

*electronic*

L12 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:561116 CAPLUS Full-text

DN 146:493555

TI Use of TAK-475 together with ezetimibe for treating hyperlipidemia

IN Nishimoto, Tomoyuki; Iino, Hiroko; Wada, Takeo

PA Takeda Pharmaceutical Company Limited, Japan

SO PCT Int. Appl., 20pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007058335	A1	20070524	WO 2006-JP323058	20061114
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-736319P	P	20051115		
AB	A pharmaceutical composition useful for a prevention and/or treatment of hyperlipidemia, which comprises combining an effective amount of Compound X and ezetimibe is provided.				
IT	189060-13-7, TAK-475				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (use of TAK-475 together with ezetimibe for treating hyperlipidemia)				
RN	189060-13-7 CAPLUS				
CN	4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)				

Absolute stereochemistry.



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1286352 CAPLUS Full-text  
 DN 146:33131  
 TI Novel method of treating hyperlipidemia using a squalene synthase inhibitor and an HMG-CoA reductase inhibitor  
 IN Nishimoto, Tomoyuki; Tozawa, Ryuichi; Wada, Takeo; Ishikawa, Eiichiro; Nishi, Toshiya; Iino, Hiroko  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 141pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006129859	A2	20061207	WO 2006-JP311362	20060531
	WO 2006129859	A3	20070419		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRAI	US 2005-685871P	P	20050601		
	US 2005-728329P	P	20051020		

OS MARPAT 146:33131

AB A pharmaceutical composition useful for a prevention and/or treatment of hyperlipidemia, which comprises combining an effective amount of squalene synthase inhibitor and HMG-CoA reductase inhibitor is provided. Thus, plasma triglycerides of Wistar Fatty rats were lowered by treatment with squalene synthase inhibitor N-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid (Compound X, 30 mg/kg) or HMG-CoA reductase inhibitor atorvastatin (30 mg/kg) from 519.7 mg/dL (vehicle) to 376.5 mg/dL for Compound X and 192.1 mg/dL for atorvastatin. By use in combination of Compound X and atorvastatin, an addnl. action of lowering plasma triglyceride was observed (142.9 mg/dL).

IT 189060-13-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. comprising squalene synthase inhibitor and HMG-CoA reductase inhibitor for prevention and/or treatment of hyperlipidemia with reduced toxicity)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1147695 CAPLUS Full-text  
 DN 145:465761  
 TI Remedy for xanthoma containing squalene synthetase inhibitor  
 IN Shiomi, Masashi; Ito, Takashi; Tozawa, Ryuichi; Amano, Yuichiro  
 PA National University Corporation Kobe University, Japan; Takeda  
 Pharmaceutical Company Limited  
 SO PCT Int. Appl., 102pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006115193	A1	20061102	WO 2006-JP308402	20060421
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI JP 2005-124781 A 20050422

OS MARPAT 145:465761

AB Disclosed is a preventive/remedy for xanthoma which contains a compound having an inhibitory effect on squalene synthase, its prodrug or its salt. For example, the effect of N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid (I) on xanthoma in rabbits was examined Also, a capsule containing I 10 mg/capsule was formulated.


IT 189060-13-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (remedies for xanthoma containing squalene synthetase inhibitors)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L12 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1039683 CAPLUS Full-text  
 DN 146:92343  
 TI Drug evaluation: TAK-475 - an oral inhibitor of squalene synthase for hyperlipidemia  
 AU Burnett, John R.  
 CS Department of Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, WA, 6847, Australia  
 SO Current Opinion in Investigational Drugs (Thomson Scientific) (2006), 7(9), 850-856  
 CODEN: COIDAZ; ISSN: 1472-4472  
 PB Thomson Scientific  
 DT Journal; General Review  
 LA English  
 AB A review. Takeda Pharmaceutical Co Ltd is developing TAK-475, a squalene synthetase inhibitor from a series of 4,1-benzoxazepine-3-acetic acid derivs., for the potential oral treatment of hyperlipidemia. By Mar. 2005, TAK-475 was undergoing phase III clin. trials in the US and Europe.  
 IT 189060-13-7P, TAK-475  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (TAK-475, squalene synthase inhibitor may be used in treatment of hyperlipidemia in patient)  
 RN 189060-13-7 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



IT 189060-13-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(benzoxazepinylacetyl piperidineacetic acid derivative as C-reactive  
protein lowering agent)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-  
dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-  
4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1328544 CAPLUS Full-text

DN 144:69867

TI Preparation of aliphatic cyclic carboxamide having carboxyl group by highly selective novel amidation without protection of carboxyl group

IN Inagaki, Atsushi; Sera, Misayo

PA Takeda Pharmaceutical Company Limited, Japan

SO PCT Int. Appl., 62 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005121133	A1	20051222	WO 2005-JP11091	20050610
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005252111	A1	20051222	AU 2005-252111	20050610
	CA 2569686	A1	20051222	CA 2005-2569686	20050610
	EP 1753752	A1	20070221	EP 2005-751255	20050610
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	IN 2006KN03429	A	20070615	IN 2006-KN3429	20061120
	NO 2007000123	A	20070307	NO 2007-123	20070108
PRAI	JP 2004-174417	A	20040611		
	WO 2005-JP11091	W	20050610		
OS	CASREACT 144:69867; MARPAT 144:69867				
GI					



I



AB The present invention provides an industrial production method with a short process having a high yield of an aliphatic cyclic carboxamide having carboxyl group. The process comprises reacting functional group-selectively using an

inexpensive condensing agent without protecting the carboxyl group by esterification, i.e., reacting carboxylic acid anhydride obtained by reacting carboxylic acid and tertiary carboxylic acid halide with aliphatic cyclic secondary amine having carboxyl group. Thus, 23.0 kg [(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-acetoxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetic acid (I) (R = OH) and 4.6 kg Et<sub>3</sub>N were added to 138 L MeCN, and 5.8 kg pivaloyl chloride was added thereto at about 0°. After reacting at 0-5° for 1 h, 9.7 kg piperidine-4-acetic acid hydrochloride and 6.7 kg Et<sub>3</sub>N were added at the same temperature. The resulting mixture was stirred at 20-28° for 30 min and treated with 0.5 N HCl (46 L) and 184 L Et acetate and the layers were separated. The organic layer was washed with 3% brine (46 L x 2), concentrated under reduced pressure to total volume of 140 L, treated with 92 L n-heptane at 75° to 55°, cooled to .apprx.5°, and stirred to mature for 1 h. The precipitated crystals were collected by filtration, and dried under reduced pressure to give 26.0 kg I (R = Q), namely [1-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid (II) (88.4% yield). II is useful for preventing and/or treating hyperlipidemia, familial hypercholesterolemia, organ failure or organ dysfunction and a method for protecting skeletal muscle. Various pharmaceutical formulations containing II were described.

IT 189060-13-7P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of carboxy-containing aliphatic cyclic carboxamide by highly selective

amidation of carboxylic acid with carboxy-containing aliphatic cyclic secondary amine via carboxylic acid anhydride without carboxy protection)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

App's

L12 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:633548 CAPLUS Full-text  
 DN 141:162403  
 TI Skeletal muscle protecting agents containing squalene synthase inhibitors  
 IN Tozawa, Ryuichi; Nishimoto, Tomoyuki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004064865	A1	20040805	WO 2004-JP234	20040115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	JP 2003277377	A	20031002	JP 2003-10125	20030117
	CA 2513170	A1	20040805	CA 2004-2513170	20040115
	EP 1600166	A1	20051130	EP 2004-702450	20040115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006052362	A1	20060309	US 2005-542322	20050713
PRAI	JP 2003-10125	A	20030117		
	JP 2003-93591	A	20030331		
	JP 2002-10623	A	20020118		
	WO 2004-JP234	W	20040115		

OS MARPAT 141:162403

AB It is intended to provide a novel drug useful as a skeletal muscle protecting agent which contains a compound having an effect of inhibiting squalene synthase, its salt or a prodrug thereof. The agent of the present invention is suitable for use for protecting skeletal muscle from cytotoxicity due to usage of other drug, e.g. HMG-CoA reductase inhibitor. The effect of N-[[ (3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid on muscle geranylgeraniol content in rats was examined

IT 189060-13-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(skeletal muscle protecting agents containing squalene synthase inhibitors)

RN 189060-13-7 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:584090 CAPLUS Full-text  
 DN 139:240092  
 TI Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro  
 AU Nishimoto, Tomoyuki; Amano, Yuichiro; Tozawa, Ryuichi; Ishikawa, Eiichiro; Imura, Yoshimi; Yukimasa, Hidefumi; Sugiyama, Yasuo  
 CS Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, Osaka, 532-8686, Japan  
 SO British Journal of Pharmacology (2003), 139(5), 911-918  
 CODEN: BJPCBM; ISSN: 0007-1188  
 PB Nature Publishing Group  
 DT Journal  
 LA English  
 AB Squalene synthase is the enzyme that converts farnesyl pyrophosphate to squalene in the cholesterol biosynthesis pathway. We examined the lipid-lowering properties of 1-[[[(3R,5S)-1-(3- acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)- 2-oxo-1,2,3,5-tetrahydro- 4,1-benzoxazepin-3-yl]acetyl]piperidine- 4-acetic acid (TAK-475), a novel squalene synthase inhibitor. TAK-475 inhibited hepatic cholesterol biosynthesis in rats (ED50, 2.9 mg kg<sup>-1</sup>) and showed lipid-lowering effects in beagle dogs, marmosets, cynomolgus monkeys and Wistar fatty rats. In marmosets, TAK-475 (30, 100 mg kg<sup>-1</sup>, p.o., for 4 days) lowered both plasma non-high-d. lipoprotein (HDL) cholesterol and triglyceride, but did not affect plasma HDL cholesterol. Atorvastatin (10, 30 mg kg<sup>-1</sup>, p.o., for 4 days) lowered the levels of all these lipids. A correlation between decrease in triglyceride and increase in HDL cholesterol was observed, and TAK-475 increased HDL cholesterol with a smaller decrease in triglyceride than did atorvastatin. TAK-475 (60 mg kg<sup>-1</sup>, p.o., for 15 days) suppressed the rate of triglyceride secretion from the liver in hypertriglyceridemic Wistar fatty rats, which show an enhanced triglyceride secretion rate from the liver compared with their lean littermates. In HepG2 cells, TAK-475 and its pharmacol. active metabolite, T-91485, increased the binding of <sup>125</sup>I-low-d. lipoprotein (LDL) to LDL receptors. These results suggest that TAK-475 has clear hypolipidemic effects in animals via inhibition of hepatic triglyceride secretion and upregulation of LDL receptors, and that TAK-475 might increase HDL cholesterol by decreasing triglyceride. Thus, TAK-475 is expected to be useful for the treatment of dyslipidemia.  
 IT 189060-13-7, TAK 475  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lipid-lowering properties of TAK-475)  
 RN 189060-13-7 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L12 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:249806 CAPLUS Full-text  
 DN 139:173582  
 TI Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia  
 AU Amano, Yuichiro; Nishimoto, Tomoyuki; Tozawa, Ryu-Ichi; Ishikawa, Eiichiro; Imura, Yoshimi; Sugiyama, Yasuo  
 CS Pharmaceutical Research Division, Pharmacology Research Laboratories II, Takeda Chemical Industries, Ltd., 2-17-85, Juso-Honmachi, Osaka, Yodogawa, 532-8686, Japan  
 SO European Journal of Pharmacology (2003), 466(1-2), 155-161  
 CODEN: EJPHAZ; ISSN: 0014-2999  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 AB The lipid-lowering effects of 1-[2-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-(2,3-dimethoxyphenyl)-4,1-benzoxazepine-3-yl] acetyl] piperidin-4-acetic acid (TAK-475), a novel squalene synthase inhibitor, were examined in two models of familial hypercholesterolemia, low-d. lipoprotein (LDL) receptor knockout mice and Watanabe heritable hyperlipidemic (WHHL) rabbits. Two weeks of treatment with TAK-475 in a diet admixt. (0.02% and 0.07%; approx. 30 and 110 mg/kg/day, resp.) significantly lowered plasma non-high-d. lipoprotein (HDL) cholesterol levels by 19% and 41%, resp., in homozygous LDL receptor knockout mice. The 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors, simvastatin and atorvastatin (in 0.02% and 0.07% admixts.), also reduced plasma levels of non-HDL cholesterol. In homozygous WHHL rabbits, 4 wk of treatment with TAK-475 (0.27%; approx. 100 mg/kg/day) lowered plasma total cholesterol, triglyceride and phospholipid levels by 17%, 52% and 26%, resp. In Triton WR-1339-treated rabbits, TAK-475 inhibited to the same extent the rate of secretion from the liver of the cholesterol, triglyceride and phospholipid components of very-low-d. lipoprotein (VLDL). These results suggest that the lipid-lowering effects of TAK-475 in WHHL rabbits are based partially on the inhibition of secretion of VLDL from the liver. TAK-475 had no effect on plasma aspartate aminotransferase and alanine aminotransferase activities. Thus, the squalene synthase inhibitor TAK-475 revealed lipid-lowering effects in both LDL receptor knockout mice and WHHL rabbits.  
 IT 189060-13-7, TAK 475  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia)  
 RN 189060-13-7 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32      THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:22711 CAPLUS Full-text

DN 138:83384

TI Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase

IN Sugiyama, Yasuo; Nishimoto, Tomoyuki; Kiyota, Yoshihiro

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2003002147	A1	20030109	WO 2002-JP6495	20020627
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2451163	A1	20030109	CA 2002-2451163	20020627
	AU 2002313277	A1	20030303	AU 2002-313277	20020627
	JP 2003081873	A	20030319	JP 2002-188133	20020627
	EP 1407782	A1	20040414	EP 2002-738822	20020627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004204500	A1	20041014	US 2003-480707	20031211
	US 2006241096	A1	20061026	US 2006-473560	20060623
PRAI	JP 2001-197419	A	20010628		
	WO 2002-JP6495	W	20020627		
	US 2003-480707	A3	20031211		

OS MARPAT 138:83384

AB Preventives/remedies for organ functional disorders, preventives/remedies for organ dysfunction and preventives/remedies for obesity and sequels thereof which contain a compound having an effect of increasing ubiquinone, its salt or prodrugs of the same; and ubiquinone increasing agents containing a compound having a squalene synthase inhibitory effect, its salt or prodrugs of the same.

IT 189060-04-6, Ethyl N-[(3R,5S)-1-(3-Acetoxy-2-acetoxy-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-Benzoxazepin-3-yl]acetyl]piperidineacetate 189060-10-4, Ethyl N-[(3R,5S)-1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidineacetate


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)

RN 189060-04-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 189060-10-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 189060-13-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:664428 CAPLUS Full-text  
 DN 137:337866  
 TI Synthesis of Novel 4,1-Benzoxazepine Derivatives as Squalene Synthase Inhibitors and Their Inhibition of Cholesterol Synthesis  
 AU Miki, Takashi; Kori, Masakuni; Mabuchi, Hiroshi; Tozawa, Ryu-ichi; Nishimoto, Tomoyuki; Sugiyama, Yasuo; Teshima, Koichiro; Yukimasa, Hidefumi  
 CS Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Yodogawa-ku, Osaka, 532-8686, Japan  
 SO Journal of Medicinal Chemistry (2002), 45(20), 4571-4580  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 137:337866  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Modification of the carboxyl group at the 3-position and introduction of protective groups to the hydroxy group of the 4,1-benzoxazepine derivative I (R = OH) [metabolite of I (R = H) Na salt] were carried out, and the inhibitory activity for squalene synthase and cholesterol synthesis in the liver was investigated. Among these compds., the glycine derivative II (n = 1) and  $\beta$ -alanine derivative II (n = 2) exhibited the most potent inhibition of squalene synthase prepared from HepG2 cells (IC<sub>50</sub> = 15 nM). On the other hand, the piperidine-4-acetic acid derivative III (R<sub>1</sub> = Ac), which was prepared by acetylation of III (R<sub>1</sub> = H), was the most effective inhibitor of cholesterol synthesis in rat liver (ED<sub>50</sub> = 2.9 mg/kg, po). After oral administration, III (R<sub>1</sub> = Ac) was absorbed and rapidly hydrolyzed to III (R<sub>1</sub> = H). Compound III (R<sub>1</sub> = H) was detected mainly in the liver, but the plasma level of III (R<sub>1</sub> = H) was found to be low. Compds. III (R<sub>1</sub> = H, Ac) were found to be competitive inhibitors with respect to farnesyl pyrophosphate. Further evaluation of III (R<sub>1</sub> = Ac) as a cholesterol-lowering and antiatherosclerotic agent is underway.  
 IT 189060-13-7P 473987-25-6P 473987-26-7P  
 473987-27-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of 4,1-benzoxazepines as squalene synthase inhibitors and their inhibition of cholesterol synthesis)  
 RN 189060-13-7 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 473987-25-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-26-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxobutoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-27-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(2-methyl-1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 473987-21-2P 473987-22-3P 473987-23-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4,1-benzoxazepines as squalene synthase inhibitors and their inhibition of cholesterol synthesis)

RN 473987-21-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 473987-22-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxobutoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-

benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-23-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(2-methyl-1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L12 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:368342 CAPLUS Full-text  
 DN 136:359669  
 TI High-density lipoprotein-cholesterol level elevating agent  
 IN Nishimoto, Tomoyuki; Tozawa, Ryuichi; Kori, Masakuni; Amano, Yuichiro  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 111 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038180	A1	20020516	WO 2001-JP9802	20011109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2428669	A1	20020516	CA 2001-2428669	20011109
	AU 2002012741	A5	20020521	AU 2002-12741	20011109
	JP 2002205956	A	20020723	JP 2001-344074	20011109
	EP 1332763	A1	20030806	EP 2001-981043	20011109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004063750	A1	20040401	US 2003-416239	20030506
PRAI	JP 2000-342607	A	20001109		
	WO 2001-JP9802	W	20011109		
OS	MARPAT 136:359669				
AB	Disclosed is a novel high-d. lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory effect. The HDL-cholesterol-elevating effect of N-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]acetyl]piperidine-4-acetic acid (I) in common marmoset was examined Also, a tablet containing I 50, D-mannitol 50, corn starch 33.9, croscarmellose sodium 40, hydroxypropyl cellulose 5.5, and magnesium stearate 0.6 mg was prepared				
IT	189060-05-7 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (high-d. lipoprotein-cholesterol level elevating agents containing squalene synthase inhibitors)				
RN	189060-05-7 CAPLUS				
CN	4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




IT 189060-04-6 189060-10-4 189060-13-7  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses).  
 (high-d. lipoprotein-cholesterol level elevating agents containing squalene synthase inhibitors)  
 RN 189060-04-6 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 189060-10-4 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:416879 CAPLUS Full-text  
 DN 135:19434  
 TI Process for production of optically active benzhydrols by asymmetric hydrogenation of benzophenone derivatives  
 IN Yamano, Toru; Oi, Satoru; Yamashita, Masayuki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001040162	A1	20010607	WO 2000-JP8392	20001129
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2001220371	A	20010814	JP 2000-362780	20001129
PRAI	JP 1999-341015	A	19991130		
OS	CASREACT 135:19434; MARPAT 135:19434				
GI					



I



II

AB A process for production of optically active compds. of general formula (I) [wherein R1 and R2 are each hydrogen or (un)substituted hydrocarbyl or acyl; ring A or B represents (un)substituted benzene ring; \* represents an asym. carbon atom] is characterized by hydrogenating a benzophenone compound of general formula (II; R1 and R2 are same above) in the presence of both an optically active ruthenium-phosphine-amine complex prepared through isolation from a phosphine represented by, e.g., the general formula PR3R4R5 (wherein R3, R4 and R5 are each optionally substituted hydrocarbyl or R3 and R4 are linked together to form a cyclic hydrocarbyl ring), an amine of the general formula NHR8R9 [wherein R8 and R9 are each hydrogen or (un)substituted hydrocarbyl] and a ruthenium complex, and a base. This process efficiently gives optically active benzhydrols, which are useful as intermediates for drugs such as squalene synthetase inhibitors and triglyceride-lowering agents, in high yields under mild conditions at low hydrogen pressure and near room temperature. Thus, 292 mg (2-amino-5-chlorophenyl)(2,3-dimethoxyphenyl)methanone and 24 mg [RuCl2[(R)-xylBINAP]][(R)-daipen] [xyl-BINAP = 2,2'-bis(dicyclohexylphosphino)-6,6'-dimethyl-1,1'-biphenyl, daipen = 1-isopropyl-2,2-bis(p-methoxyphenyl)ethylenediamine] (REG 220114-32-9) were added to a glass autoclave, followed by purging the autoclave with Ar and adding a solution of 0.03 mL 1.0 M Me3COK/Me3COH and 2 mL toluene which had

been purged with Ar, and the resulting mixture was purged with Ar and stirred at room temperature under hydrogen pressure of 7 atm to give 97.1% (S)-(2-amino-5-chlorophenyl)(2,3-dimethoxyphenyl)methanol (98.7% e.e.). The latter compound was converted in 8 steps into N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid which is a known squalene synthetase inhibitor.

IT 189060-13-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(process for production of optically active benzhydrols by asym.

hydrogenation of benzophenone derivs. in presence of optically active ruthenium phosphine amine complex)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1997:317788 CAPLUS Full-text  
 DN 126:293368  
 TI Benzoxazepine compounds, their production and use as lipid lowering agents  
 IN Yukimasa, Hidefumi; Sugiyama, Yasuo; Tozawa, Ryuichi  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 112 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9710224	A1	19970320	WO 1996-JP2596	19960912
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2231052	A1	19970320	CA 1996-2231052	19960912
	AU 9669442	A	19970401	AU 1996-69442	19960912
	JP 09136880	A	19970527	JP 1996-242378	19960912
	JP 3479796	B2	20031215		
	EP 862562	A1	19980909	EP 1996-930365	19960912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1196052	A	19981014	CN 1996-196892	19960912
	CN 1072649	B	20011010		
	JP 2001097963	A	20010410	JP 2000-323310	19960912
	EP 1097928	A1	20010509	EP 2000-126672	19960912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 202774	T	20010715	AT 1996-930365	19960912
	ES 2158344	T3	20010901	ES 1996-930365	19960912
	PT 862562	T	20011130	PT 1996-930365	19960912
	ZA 9702134	A	19990604	ZA 1997-2134	19970312
	US 6110909	A	20000829	US 1998-43265	19980312
	US 6613761	B1	20030902	US 2000-587947	20000606
	GR 3036707	T3	20011231	GR 2001-401564	20010926
	US 2004072819	A1	20040415	US 2003-606152	20030624
	US 2007117787	A1	20070524	US 2006-638066	20061212
PRAI	JP 1995-235457	A	19950913		
	EP 1996-930365	A3	19960912		
	JP 1996-242378	A3	19960912		
	WO 1996-JP2596	W	19960912		
	ZA 1997-2134	A	19970312		
	US 1998-43265	A3	19980312		
	US 2000-587947	A1	20000606		
	US 2003-606152	B1	20030624		
OS	MARPAT 126:293368				
GI					



AB New benzoxazepines I [R = alkyl, hydroxyalkyl; R1 = alkyl; R2 = halogen; R3 = (un)substituted CONH2, heterocyclic group having a deprotonatable hydrogen atom] were prepared for use as cholesterol and triglyceride lowering agent. Thus, I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = CO2H] was amidated, dehydrated to the nitrile, and cyclized with Me3SiN3 to give I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = 5-tetrazolyl] which had a squalene synthetase inhibiting IC50 of 11X10<sup>-9</sup> M.


IT 189060-04-6P 189060-05-7P 189060-10-4P  
189060-13-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of arylbenzoxazepinones as hypolipemic agents)

RN 189060-04-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 189060-05-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-10-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.






=> d l2; d l9; d his; log y  
 L2 HAS NO ANSWERS  
 L1 STR



Structure attributes must be viewed using STN Express query preparation.  
 L2 QUE ABB=ON PLU=ON L1

L9 HAS NO ANSWERS  
 L8 STR



Structure attributes must be viewed using STN Express query preparation.  
 L9 QUE ABB=ON PLU=ON L8

(FILE 'REGISTRY' ENTERED AT 16:02:36 ON 02 JUL 2007)

DEL HIS Y  
 L1 STRUCTURE UPLOADED  
 L2 QUE L1  
 L3 41 S L2  
 L4 896 S L2 FUL

FILE 'CAPLUS' ENTERED AT 16:05:44 ON 02 JUL 2007  
 L5 29 S L4

FILE 'STNGUIDE' ENTERED AT 16:07:25 ON 02 JUL 2007

FILE 'REGISTRY' ENTERED AT 16:11:01 ON 02 JUL 2007

L6 STRUCTURE UPLOADED  
 L7 QUE L6  
 L8 STRUCTURE UPLOADED

L9                    QUE L8  
L10                  1 S L9 SAM SUB=L4  
L11                  10 S L9 FUL SUB=L4

FILE 'CAPLUS' ENTERED AT 16:12:33 ON 02 JUL 2007  
L12                  14 S L11


COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	74.25	618.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-10.92	-33.54

STN INTERNATIONAL LOGOFF AT 16:13:17 ON 02 JUL 2007

RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-04-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-(propylsulfonyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-14-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(butylsulfonyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-20-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-N-[[3-(acetyloxy)propyl]sulfonyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-31-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[[3-(phenylthio)propyl]sulfonyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-40-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[[3-(2-pyridinylthio)propyl]sulfonyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-71-2 CAPLUS

CN D-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-03-3 CAPLUS

CN L-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-14-6 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-54-4 CAPLUS

CN Benzeneacetic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-65-7 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-88-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-99-7 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-09-2 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-19-4 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383655-31-0 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-41-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-ethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-52-5 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-73-0 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383655-93-4 CAPLUS

CN Benzeneacetic acid, 4-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-19-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,5-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-30-2 CAPLUS

CN Benzenebutanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-42-6 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-68-6 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-78-8 CAPLUS

CN Benzoic acid, 4-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-90-4 CAPLUS

CN Propanoic acid, 2-[4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-01-0 CAPLUS

CN Acetic acid, [4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-12-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-22-5 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-38-3 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-50-9 CAPLUS

CN Benzoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-61-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-72-5 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-83-8 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-94-1 CAPLUS

CN Benzeneacetic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383658-05-7 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-15-9 CAPLUS

CN Benzoic acid, 3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-25-1 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-36-4 CAPLUS

CN Benzoic acid, 4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-46-6 CAPLUS

CN Benzoic acid, 3-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-84-2 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-95-5 CAPLUS

CN Hexanoic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-31-2 CAPLUS

CN Benzenepropanoic acid, 4-chloro-3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




(title compds.; preparation of dialkoxyphenyloxobenzoxazepineacetamide  
squalene synthase inhibitors as antihyperlipidemic and

antihypercholesteremic agents)

RN 383652-05-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-(propylsulfonyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-11-7 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-16-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-22-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-28-6 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383652-38-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-50-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-61-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-71-9 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-76-4 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383652-81-1 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-87-7 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-09-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-N-(butylsulfonyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-25-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-[(3-hydroxypropyl)sulfonyl]-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-35-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(phenylthio)propyl)sulfonyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-45-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(2-pyridinylthio)propyl]sulfonyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383653-66-5 CAPLUS

CN L-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-76-7 CAPLUS

CN D-Leucine, N-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-81-4 CAPLUS

CN D-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-86-9 CAPLUS

CN L-Methionine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-92-7 CAPLUS

CN D-Methionine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-97-2 CAPLUS

CN D-Methionine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-09-9 CAPLUS

CN L-Alanine, N-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-20-4 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-25-9 CAPLUS


CN Cyclohexanepropanoic acid,  $\alpha$ -[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 383654-30-6 CAPLUS  
 CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383654-36-2 CAPLUS  
 CN 2,4-Furandicarboxylic acid, 5-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 383654-41-9 CAPLUS  
 CN 2-Furancarboxylic acid, 5-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-46-4 CAPLUS

CN 2-Furancarboxylic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-60-2 CAPLUS

CN Benzeneacetic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383654-70-4 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-76-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-82-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-94-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-04-7 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-14-9 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-25-2 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-36-5 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-46-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-ethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-57-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383655-78-5 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383655-83-2 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383655-98-9 CAPLUS

CN Benzeneacetic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-06-2 CAPLUS

CN Benzenepropanoic acid, 4-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-24-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,5-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-36-8 CAPLUS

CN Benzenebutanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-63-1 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-73-3 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-84-6 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383656-95-9 CAPLUS

CN Propanoic acid, 2-[4-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383657-07-6 CAPLUS

CN Acetic acid, [4-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-17-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-27-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-32-7 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-44-1 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-55-4 CAPLUS

CN Benzoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-67-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-78-1 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-89-4 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-99-6 CAPLUS

CN Benzeneacetic acid, 4-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-10-4 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-20-6 CAPLUS

CN Benzoic acid, 3-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-30-8 CAPLUS

CN Benzoic acid, 3-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-40-0 CAPLUS

CN Benzoic acid, 4-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-51-3 CAPLUS

CN Benzoic acid, 3-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluorobenzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-57-9 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-62-6 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-68-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-74-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-79-5 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383658-90-0 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-00-5 CAPLUS

CN Hexanoic acid, 6-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-06-1 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 383659-21-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 383659-26-5 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-chloro- (9CI) (CA INDEX NAME)

CN Benzenepropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)

Chemical structure of compound 10: A complex molecule featuring a 4-(3-phenylpropoxy)benzoic acid moiety linked via an amide bond to a 2-oxo-1,3-dioxolane ring. This ring is further substituted with a 4-chlorophenyl group, a 3,4-dimethoxyphenyl group, and a 2-hydroxy-2-methylpropyl group.

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(3-phenylpropoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-55-0 CAPLUS

CN 1-Naphthalenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383659-61-8 CAPLUS

CN 1-Naphthalenecarboxylic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-

4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-67-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-73-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-79-8 CAPLUS

CN Benzoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-84-5 CAPLUS

CN Benzoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-89-0 CAPLUS

CN Acetic acid, [4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]phenoxy]difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-94-7 CAPLUS

CN Acetic acid, [3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]phenoxy]difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383659-99-2 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-05-7 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-11-5 CAPLUS

CN Acetic acid, [4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-fluorophenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383660-16-0 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-21-7 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- $\gamma,\gamma$ -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-26-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-32-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-38-6 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-43-3 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-48-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-52-4 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-57-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-62-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-67-1 CAPLUS

CN Acetic acid, [[5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-1H-benzimidazol-2-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-72-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-77-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-ethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-82-0 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-propoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-87-5 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-93-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383660-98-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-propoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-03-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 3-(carboxymethoxy)-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-08-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-12-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-(1-methylethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383661-17-4 CAPLUS

CN Benzo[b]thiophene-2-carboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-22-1 CAPLUS

CN 2-Benzofuranpropanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-27-6 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-31-2 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-36-7 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-40-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-45-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,6,7-trimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383661-50-5 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-chloro-7-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:932483 CAPLUS Full-text  
 DN 136:50294  
 TI Drug design of squalene synthase inhibitors by X-ray structure computer analysis  
 IN Usui, Hiroyuki; Katakura, Shinichi; Suzuki, Makoto  
 PA Daiichi Seiyaku Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 131 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001354587	A	20011225	JP 2000-177413	20000613
PRAI	JP 2000-177413		20000613		
GI					



AB A method for designing inhibitors of squalene synthase by computer anal. of X-ray crystallog. structure of the enzyme complexed with the known inhibitors, is disclosed. Divalent metal ion binding or hydrogen bonding by the carboxyl groups of Asp80, Glu83, and Asp84, or Asp219, Glu222, and Asp223, are used for inhibition. The compds. having the general structure I (Ar = possibly substituted single or double aromatic ring, R1 = single or double ring aromatic heterocycle, possibly substituted with single or double ring aromatic heterocycle, or C2-C6 alkenyl, A1 and A2 = C, O, S, CH, CR2, CH2, CHR3, C=O, NH, or NR4 (R2, R3, and R4 = C1-C6 alkyl)) or II (R1, A1, A2, same as above, B and Y = C, O, S, CH, CR2, CH2, CHR3, C=O, NH, or NR4 (R2, R3, and R4 = C1-C6 alkyl)), as preventive or therapeutic agent for hypercholesterolemia are claimed. Crystals of the complex of the soluble domain of squalene synthase (amino acid residues 31-370) with previously known inhibitors, D-61-7267 (III) (WO 9829380) and D-91-1169 (IV) (JP 09186880) were obtained and the three dimensional structures were determined. Hydrophobic van der Waals interactions between naphthalene rings A and B of III, or benzene ring A of IV, and hydrophobic amino acids, Val179, Leu183, Met207, Gly208, Leu211, Tyr276, Phe288, and Pro292 was detected. Likewise, interactions between naphthalene rings C and D of III, or benzene ring B of IV, and hydrophobic amino acids Phe54, Val69, Phe72, Tyr73, Leu76, Val179, Leu183, and Phe288, were observed.

IT 189058-86-4, D 91-1169


RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug design of squalene synthase inhibitors by x-ray structure computer anal.)


RN 189058-86-4 CAPLUS

CN L-Aspartic acid, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:900250 CAPLUS Full-text  
 DN 136:272650  
 TI Novel 4,1-benzoxazepine derivatives with potent squalene synthase inhibitory activities  
 AU Miki, Takashi; Kori, Masakuni; Mabuchi, Hiroshi; Banno, Hiroshi; Tozawa, Ryu-ichi; Nakamura, Masahira; Itokawa, Shigekazu; Sugiyama, Yasuo; Yukimasa, Hidefumi  
 CS Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Yodogawa-ku, Juso-Honmachi, Osaka, 532-8686, Japan  
 SO Bioorganic & Medicinal Chemistry (2001), Volume Date 2002, 10(2), 401-414  
 CODEN: BMECEP; ISSN: 0968-0896  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 136:272650  
 GI



I

AB A series of (3,5-trans)-2-oxo-5-phenyl-1,2,3,5-tetrahydro-4,1- benzoxazepine derivs. were synthesized and evaluated for squalene synthase inhibitory and cholesterol biosynthesis inhibitory activities. Through modification of substituents of the lead compds., it was found that 4,1-benzoxazepine-3-acetic acid derivs. with iso-Bu and neopentyl groups at the 1-position, the chloro atom at the 7-position, and the chloro and methoxy groups at the 2'-position on the 5-Ph ring, had potent squalene synthase inhibitory activity. Among such compds., the 5-(2,3-dimethoxyphenyl) derivative I exhibited potent inhibition of cholesterol biosynthesis in HepG2 cells. As a result of optical resolution study of I, the absolute stereochem. required for inhibitory activity was determined to be 3R,5S. In vivo study showed that the sodium salt of (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid effectively reduced plasma cholesterol in marmosets.  
 IT 406684-80-8P 406684-81-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of benzoxazepine derivs. with potent squalene synthase inhibitory activities)  
 RN 406684-80-8 CAPLUS  
 CN L-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 406684-81-9 CAPLUS

CN L-Leucine, N-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:416879 CAPLUS Full-text  
 DN 135:19434  
 TI Process for production of optically active benzhydrols by asymmetric  
 hydrogenation of benzophenone derivatives  
 IN Yamano, Toru; Oi, Satoru; Yamashita, Masayuki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001040162	A1	20010607	WO 2000-JP8392	20001129
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2001220371	A	20010814	JP 2000-362780	20001129
PRAI	JP 1999-341015	A	19991130		
OS	CASREACT 135:19434; MARPAT 135:19434				
GI					



I



II

AB A process for production of optically active compds. of general formula (I) [wherein R1 and R2 are each hydrogen or (un)substituted hydrocarbyl or acyl; ring A or B represents (un)substituted benzene ring; \* represents an asym. carbon atom] is characterized by hydrogenating a benzophenone compound of general formula (II; R1 and R2 are same above) in the presence of both an optically active ruthenium-phosphine-amine complex prepared through isolation from a phosphine represented by, e.g., the general formula PR3R4R5 (wherein R3, R4 and R5 are each optionally substituted hydrocarbyl or R3 and R4 are linked together to form a cyclic hydrocarbyl ring), an amine of the general formula NHR8R9 [wherein R8 and R9 are each hydrogen or (un)substituted hydrocarbyl] and a ruthenium complex, and a base. This process efficiently gives optically active benzhydrols, which are useful as intermediates for drugs such as squalene synthetase inhibitors and triglyceride-lowering agents, in high yields under mild conditions at low hydrogen pressure and near room temperature. Thus, 292 mg (2-amino-5-chlorophenyl)(2,3-dimethoxyphenyl)methanone and 24 mg [RuCl2[(R)-xylBINAP]][(R)-daipen] [xyl-BINAP = 2,2'-bis(dicyclohexylphosphino)-6,6'-dimethyl-1,1'-biphenyl, daipen = 1-isopropyl-2,2-bis(p-methoxyphenyl)ethylenediamine] (REG 220114-32-9) were added to a glass autoclave, followed by purging the autoclave with Ar and adding a solution of 0.03 mL 1.0 M Me3COK/Me3COH and 2 mL toluene which had been purged with Ar, and the resulting mixture was purged with Ar and stirred at room temperature under hydrogen pressure of 7 atm to give 97.1% (S)-(2-



amino-5- chlorophenyl)(2,3-dimethoxyphenyl)methanol (98.7% e.e.). The latter compound was converted in 8 steps into N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid which is a known squalene synthetase inhibitor.

IT 189059-65-2P 189059-71-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(process for production of optically active benzhydrols by asym. hydrogenation of benzophenone derivs. in presence of optically active ruthenium phosphine amine complex)

RN 189059-65-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 189060-13-7P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for production of optically active benzhydrols by asym.  
hydrogenation of benzophenone derivs. in presence of optically active  
ruthenium phosphine amine complex)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-  
dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-  
4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 8      THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1998:709062 CAPLUS Full-text  
 DN 129:330745  
 TI Preparation of 4,1-benzoxazepines as somatostatin agonists.  
 IN Mabuchi, Hiroshi; Suzuki, Nobuhiro; Miki, Takashi  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 377 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847882	A1	19981029	WO 1998-JP1797	19980420
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2285664	A1	19981029	CA 1998-2285664	19980420
	AU 9868545	A	19981113	AU 1998-68545	19980420
	JP 11209356	A	19990803	JP 1998-109869	19980420
	EP 979227	A1	20000216	EP 1998-914096	19980420
	EP 979227	B1	20051116		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 309993	T	20051215	AT 1998-914096	19980420
	US 6352982	B1	20020305	US 1999-403066	19991014
PRAI	JP 1997-103138	A	19970421		
	JP 1997-319545	A	19971120		
	WO 1998-JP1797	W	19980420		
OS	MARPAT 129:330745				
GI					



AB Title compds. [I; A = atoms to form a (substituted) (hetero)aromatic ring; B = (substituted) (hetero)aromatic ring; Z = (substituted) cyclic group, linear hydrocarbon group; R1 = H, (substituted) hydrocarbyl, heterocyclyl; R2 = (substituted) amino; D = bond, (substituted) divalent hydrocarbyl; E = bond, CON(Ra), N(Ra)CO, N(Rb)CON(Rc), N(Rd)CO2, N(Re)SO2, CO2, N(Rf), O, S, SO, SO2, N-carboxypiperidin-4-yl, N-carboxypiperazin-4-yl; Ra-Rf = H, (substituted) hydrocarbyl; G = bond, divalent (substituted) hydrocarbyl; L = divalent group; R2B = (substituted) non-aromatic condensed N-heterocyclyl; X = H2, O, S; dotted line = optional double bond; Y = N when dotted line = double bond, or O, NR4, S, SO, SO2; R4 = H, (substituted) hydrocarbyl, acyl; when dotted line = single bond], were prepared. Thus, 3,5-trans-N-(2-fluorobenzyl)-5-(3-aminomethylphenyl)-1-(4-biphenylmethyl)-7-chloro-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide hydrochloride (multistep preparation given) at 3 mg/kg i.p. in rats reduced plasma growth hormone concns. from 92 ng/mL (controls) to 11.2 ng/mL.

IT 215187-05-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 4,1-benzoxazepines as somatostatin agonists)

RN 215187-05-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[4-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.





● HCl

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1998:180583 CAPLUS Full-text  
 DN 128:230397  
 TI Preparation of 4,1-benzoxazepin-2-one derivatives and their uses  
 IN Yukimasa, Hidefumi; Tozawa, Ryuichi; Kori, Masakuni; Kitano, Kazuaki;  
 Sugiyama, Yasuo  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO U.S., 105 pp., Cont.-in-part of U.S. Ser. No. 195,131, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5726306	A	19980310	US 1994-338163	19941109
	US 5885979	A	19990323	US 1997-852292	19970507
PRAI	JP 1992-99541	A	19920420		
	JP 1992-339947	A	19921221		
	US 1993-49455	B1	19930420		
	US 1994-195131	B2	19940209		
	JP 1994-244136	A	19941007		
	US 1994-338163	A3	19941109		
OS	MARPAT 128:230397				
GI					




AB Title compds. I (R = halogen; R1 = H, benzyl, alkyl, alkynyl, etc.; R2 = H, alkyl, Ph, heterocyclic, etc.; R3 = H, alkyl, Ph, heterocyclic, etc.; X = bond, spacer with chain length of 1-7 atoms; Y = carboxyl, alkoxy carbonyl, hydroxyl, amino group, Ph, carbamoyl group, etc.) and salts are prepared from condensation of II with 5-oxo-tetrahydro-2-furancarboxyl chloride and ClCO(Z)nCOOR4 ((Z)n = (CH2)3, CHCl(CH2)2, trans-CH:CH, etc.; R4 = H, Et, etc.). Title compds. I are useful for inhibiting squalene synthetase and fungal growth, and which are useful for treating or preventing hyperlipidemia in oral tablets or injections.  
 IT 171768-62-0P 171768-63-1P 171768-64-2P  
 171768-74-4P 171868-45-4P 171868-46-5P  
 171868-47-6P 171868-48-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepinone derivs. and their uses)

RN 171768-62-0 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171768-63-1 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171768-64-2 CAPLUS

CN L-Leucine, N-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171768-74-4 CAPLUS

CN L-Alanine, N-[[7-chloro-1-(2,2-dimethylpropyl)-5-(4-ethoxy-2-methoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171868-45-4 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171868-46-5 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171868-47-6 CAPLUS

CN L-Leucine, N-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171868-48-7 CAPLUS

CN L-Alanine, N-[[7-chloro-1-(2,2-dimethylpropyl)-5-(4-ethoxy-2-methoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1998:31309 CAPLUS Full-text  
 DN 128:102107  
 TI Preparation of 4,1-benzoxazepines and 4,1-benzothiazepines and their use  
 as squalene synthetase inhibitors  
 IN Hamanaka, Ernest Seiichi; Hayward, Cheryl Myers  
 PA Pfizer Inc., USA  
 SO PCT Int. Appl., 141 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9748701	A1	19971224	WO 1997-IB550	19970514
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
	RW:				
	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9724016	A	19980107	AU 1997-24016	19970514
	IN 1997DE01620	A	20050311	IN 1997-DE1620	19970717
	US 6537987	B1	20030325	US 1998-202106	19981218
PRAI	US 1996-22365P	P	19960620		
	WO 1997-IB550	W	19970514		
OS	MARPAT 128:102107				
GI					



II

AB The invention relates to certain benzoxazepinones and benzothiazepinones I and their pharmaceutically acceptable cationic and anionic salts, prodrugs, and stereoisomers [wherein X = O, S, S(O), or S(O)<sub>2</sub>; Y = CO or CH<sub>2</sub>; T = 4- to 7-membered mono-aza saturated heterocycle bound at N, optionally containing thio

or oxo and optionally monosubstituted on C with OH, Cl-4 alkoxy, or CO<sub>2</sub>H; Z = CO<sub>2</sub>H or derivs., including tetrazol-5-yl; Z1 = H, CO<sub>2</sub>H, OH, alkoxy, alkoxy carbonyl; R1, R2 = H, halo, OH, CF<sub>3</sub>, alkyl, fluoroalkyl, alkoxy, Ph, amino, certain heterocyclyl, etc.; R3 = (un)substituted Ph; R4 = (un)substituted alkyl, alkenyl, cycloalkylmethyl, or heterocyclylalkyl]. The compds. are useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, anti-Alzheimer's agents, and anti-acne agents (no data). Examples include over 200 invention compds. For instance, reductive alkylation of 4-ClC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> with pivaldehyde and NaBH<sub>4</sub> gave 99% 4-ClC<sub>6</sub>H<sub>4</sub>NHCH<sub>2</sub>CMe<sub>3</sub>, which reacted with BCl<sub>3</sub> and then 2,3-ethylenedioxybenzaldehyde and Et<sub>3</sub>N to give 88% (5-chloro-2-neopentylaminophenyl)(2,3-ethylenedioxyphenyl)methanol. The latter underwent a sequence of amidation with (E)-ClCOCH:CHCO<sub>2</sub>Et (90%), cyclization by treatment with K<sub>2</sub>CO<sub>3</sub> in EtOH (67%), alkaline saponification of the ester (91%), and amidation with Et isonipecotate (68%), to give title compound II.


IT 201218-86-2P 201218-89-5P 201218-92-0P  
 201218-95-3P 201219-01-4P 201219-03-6P  
 201219-04-7P 201219-05-8P 201219-06-9P  
 201219-11-6P 201219-13-8P 201219-14-9P  
 201219-23-0P 201219-26-3P 201219-28-5P  
 201219-36-5P 201219-37-6P 201219-74-1P  
 201219-75-2P 201219-86-5P 201219-87-6P  
 201219-89-8P 201219-90-1P 201219-94-5P  
 201219-98-9P 201219-99-0P 201220-00-0P  
 201220-01-1P 201220-04-4P 201220-06-6P  
 201220-07-7P 201220-16-8P 201220-19-1P  
 201220-21-5P 201220-29-3P 201220-30-6P  
 201220-71-5P 201220-72-6P 201221-11-6P  
 201419-55-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of benzoxazepines and benzothiazepines as squalene synthetase inhibitors)

RN 201218-86-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 201218-89-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-,

ethyl ester, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201218-92-0 CAPLUS

CN L-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201218-95-3 CAPLUS

CN 2,4-Piperidinedicarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dimethyl ester, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-01-4 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-03-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-04-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-05-8 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-06-9 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-5-(2,3,4-trimethoxyphenyl)-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 201219-11-6 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-1-(2,2-dimethylpropyl)-5-(2-ethoxy-4-methoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 201219-13-8 CAPLUS  
 CN L-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201219-14-9 CAPLUS  
 CN D-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201219-23-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2-chloro-3,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-26-3 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2-chloro-3,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



CN 3-Azetidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)


[illegible]

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-1-(cyclopropylmethyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-1-(cyclopropylmethyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 201219-74-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-9-fluoro-1,2,3,5-tetrahydro-7-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-75-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-9-fluoro-1,2,3,5-tetrahydro-7-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-86-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-87-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-89-8 CAPLUS

CN L-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201219-90-1 CAPLUS

CN 2,4-Piperidinedicarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-94-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,4-dimethoxy-3-methylphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-98-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201219-99-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-00-0 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-01-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-5-(2,3,4-trimethoxyphenyl)-4,1-benzoxazepin-3-yl]acetyl]-, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-04-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-1-(2,2-dimethylpropyl)-5-(2-ethoxy-4-methoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-06-6 CAPLUS

CN L-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201220-07-7 CAPLUS

CN D-Proline, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201220-16-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2-chloro-3,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-19-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2-chloro-3,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-21-5 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-29-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[7-chloro-1-(cyclopropylmethyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201220-30-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[[7-chloro-1-(cyclopropylmethyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 201220-71-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-9-fluoro-1,2,3,5-tetrahydro-7-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 201220-72-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-9-fluoro-1,2,3,5-tetrahydro-7-methyl-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3 $\alpha$ ,5 $\beta$ )-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 201221-11-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 201419-55-8 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, trans-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




L5 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1997:317788 CAPLUS Full-text  
 DN 126:293368  
 TI Benzoxazepine compounds, their production and use as lipid lowering agents  
 IN Yukimasa, Hidefumi; Sugiyama, Yasuo; Tozawa, Ryuichi  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 112 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9710224	A1	19970320	WO 1996-JP2596	19960912
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2231052	A1	19970320	CA 1996-2231052	19960912
	AU 9669442	A	19970401	AU 1996-69442	19960912
	JP 09136880	A	19970527	JP 1996-242378	19960912
	JP 3479796	B2	20031215		
	EP 862562	A1	19980909	EP 1996-930365	19960912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1196052	A	19981014	CN 1996-196892	19960912
	CN 1072649	B	20011010		
	JP 2001097963	A	20010410	JP 2000-323310	19960912
	EP 1097928	A1	20010509	EP 2000-126672	19960912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 202774	T	20010715	AT 1996-930365	19960912
	ES 2158344	T3	20010901	ES 1996-930365	19960912
	PT 862562	T	20011130	PT 1996-930365	19960912
	ZA 9702134	A	19990604	ZA 1997-2134	19970312
	US 6110909	A	20000829	US 1998-43265	19980312
	US 6613761	B1	20030902	US 2000-587947	20000606
	GR 3036707	T3	20011231	GR 2001-401564	20010926
	US 2004072819	A1	20040415	US 2003-606152	20030624
	US 2007117787	A1	20070524	US 2006-638066	20061212
PRAI	JP 1995-235457	A	19950913		
	EP 1996-930365	A3	19960912		
	JP 1996-242378	A3	19960912		
	WO 1996-JP2596	W	19960912		
	ZA 1997-2134	A	19970312		
	US 1998-43265	A3	19980312		
	US 2000-587947	A1	20000606		
	US 2003-606152	B1	20030624		
OS	MARPAT 126:293368				
GI					




- AB New benzoxazepines I [R = alkyl, hydroxyalkyl; R1 = alkyl; R2 = halogen; R3 = (un)substituted CONH2, heterocyclic group having a deprotonatable hydrogen atom] were prepared for use as cholesterol and triglyceride lowering agent. Thus, I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = CO2H] was amidated, dehydrated to the nitrile, and cyclized with Me3SiN3 to give I [R = CH2CMe3, R1 = Me, R2 = Cl, R3 = 5-tetrazolyl] which had a squalene synthetase inhibiting IC50 of  $11 \times 10^{-9}$  M.
- IT 189058-78-4P 189059-51-6P 189059-84-5P  
189059-85-6P 189059-92-5P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of arylbenzoxazepinones as hypolipemic agents)
- RN 189058-78-4 CAPLUS
- CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 189059-51-6 CAPLUS
- CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-84-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-85-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Phosphonic acid, [[1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyl]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of arylbenzoxazepinones as hypolipemic agents)

CN D-Isoleucine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)

CN L-Glutamic acid, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 5-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-86-4 CAPLUS

CN L-Aspartic acid, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-88-6 CAPLUS

CN Glycine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-91-1 CAPLUS

CN L-Phenylalanine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-94-4 CAPLUS

CN Acetic acid, [1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyldene]-  
, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189058-95-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 189058-96-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-97-7 CAPLUS

CN  $\beta$ -Alanine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-02-7 CAPLUS

CN L-Tyrosine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-05-0 CAPLUS

CN L-Valine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-06-1 CAPLUS

CN L-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-07-2 CAPLUS

CN 1-Piperazineacetic acid, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-54-9 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-3-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-55-0 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, monosodium salt, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 189059-72-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-79-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methylphenyl)sulfonyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-80-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(phenylsulfonyl)-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-81-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(1-methylethyl)sulfonyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-82-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-N-(ethylsulfonyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-83-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-90-3 CAPLUS

CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-91-4 CAPLUS

CN Phosphonic acid, [[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-93-6 CAPLUS

CN Piperidine, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-(1H-tetrazol-5-ylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-96-9 CAPLUS

CN Piperidine, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-[2-(1H-tetrazol-5-yl)ethyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-98-1 CAPLUS

CN Phosphonic acid, [[[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 189058-37-5P 189058-38-6P 189058-39-7P  
 189058-40-0P 189058-41-1P 189058-42-2P  
 189058-43-3P 189058-44-4P 189058-45-5P  
 189058-46-6P 189058-47-7P 189058-48-8P  
 189058-49-9P 189058-50-2P 189058-51-3P  
 189058-52-4P 189058-53-5P 189058-54-6P  
 189058-55-7P 189058-56-8P 189058-57-9P  
 189058-58-0P 189058-59-1P 189058-61-5P  
 189058-62-6P 189058-63-7P 189058-64-8P  
 189058-65-9P 189058-66-0P 189058-67-1P  
 189058-68-2P 189058-69-3P 189058-70-6P  
 189058-71-7P 189058-72-8P 189058-73-9P  
 189058-74-0P 189058-75-1P 189058-76-2P  
 189059-10-7P 189059-40-3P 189059-42-5P  
 189059-52-7P 189059-57-2P 189059-62-9P  
 189059-63-0P 189059-64-1P 189059-65-2P  
 189059-66-3P 189059-67-4P 189059-68-5P  
 189059-69-6P 189059-71-0P 189059-94-7P  
 189059-95-8P 189059-97-0P 189060-00-2P  
 189060-01-3P 189060-02-4P 189060-21-7P  
 189060-24-0P 189060-30-8P 189060-41-1P




RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of arylbenzoxazepinones as hypolipemic agents)

RN 189058-37-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-38-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-39-7 CAPLUS

CN Glycine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-40-0 CAPLUS

CN D-Serine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-41-1 CAPLUS

CN D-Threonine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189058-42-2 CAPLUS

CN L-Proline, 1-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-43-3 CAPLUS

CN L-Proline, 1-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-44-4 CAPLUS

CN D-Isoleucine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN L-Glutamic acid, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 5-ethyl 1-methyl ester (9CI) (CA INDEX NAME)

CN L-Aspartic acid, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)

CN L-Methionine, N-[[ (3R, 5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-48-8 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-49-9 CAPLUS

CN L-Serine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189058-50-2 CAPLUS

CN L-Asparagine, N2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-51-3 CAPLUS

CN L-Phenylalanine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-52-4 CAPLUS

CN L-Glutamine, N2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-53-5 CAPLUS

CN L-Threonine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-54-6 CAPLUS

CN Acetic acid, [1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyldene]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-55-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-56-8 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-57-9 CAPLUS

CN  $\beta$ -Alanine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189058-58-0 CAPLUS



CN Cyclohexanecarboxylic acid, 4-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester, [3R-[trans(trans)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-59-1 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-61-5 CAPLUS

CN Benzeneacetic acid, 4-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-62-6 CAPLUS

CN L-Tyrosine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-63-7 CAPLUS


CN L-Histidine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189058-64-8 CAPLUS


CN L-Tryptophan, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 189058-65-9 CAPLUS

CN L-Valine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-66-0 CAPLUS

CN L-Leucine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-67-1 CAPLUS

CN 1-Piperazineacetic acid, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-2-oxo-, 1,1-dimethylethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-68-2 CAPLUS

CN 4-Piperidinepentanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-69-3 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-70-6 CAPLUS

CN 2-Butenoic acid, 4-[1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidiny]-, ethyl ester, [3R-[3 $\alpha$ (E),5 $\beta$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 189058-71-7 CAPLUS

CN 4-Piperidineacetic acid, 4-(acetyloxy)-1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-72-8 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-73-9 CAPLUS

CN Phosphonic acid, [[1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyl]methyl]-, bis(1-methylethyl) ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-74-0 CAPLUS

CN Phosphonic acid, [[[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, diethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-75-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-76-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


.Absolute stereochemistry.



RN 189059-10-7 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-40-3 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-42-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 189059-52-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-57-2 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-(3-hydroxy-2,2-dimethylpropyl)-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-62-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-(3-cyanopropyl)-5-(2,3-

dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-  
, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-63-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-N-(3-cyanopropyl)-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-  
, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-64-1 CAPLUS

CN 1H-Tetrazole-1-propanenitrile, 5-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-65-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-66-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-67-4 CAPLUS

CN Acetic acid, [1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyldene]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-68-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-69-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-94-7 CAPLUS

CN 4-Piperidineacetamide, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-95-8 CAPLUS

CN 4-Piperidineacetonitrile, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-97-0 CAPLUS

CN Phosphonic acid, [[[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, diethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-00-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-01-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-02-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-21-7 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189060-24-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 189060-30-8 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-41-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 189058-77-3P 189058-79-5P 189058-80-8P  
 189058-81-9P 189058-82-0P 189058-83-1P  
 189058-87-5P 189058-89-7P 189058-90-0P  
 189058-92-2P 189058-93-3P 189058-98-8P  
 189058-99-9P 189059-01-6P 189059-03-8P  
 189059-04-9P 189059-08-3P 189059-09-4P  
 189059-11-8P 189059-12-9P 189059-13-0P  
 189059-14-1P 189059-15-2P 189059-16-3P  
 189059-17-4P 189059-18-5P 189059-19-6P  
 189059-20-9P 189059-21-0P 189059-22-1P  
 189059-23-2P 189059-24-3P 189059-25-4P  
 189059-26-5P 189059-27-6P 189059-28-7P  
 189059-29-8P 189059-30-1P 189059-31-2P  
 189059-32-3P 189059-33-4P 189059-34-5P  
 189059-35-6P 189059-36-7P 189059-37-8P  
 189059-38-9P 189059-39-0P 189059-41-4P  
 189059-43-6P 189059-44-7P 189059-45-8P  
 189059-46-9P 189059-47-0P 189059-48-1P  
 189059-49-2P 189059-50-5P 189059-56-1P  
 189059-70-9P 189059-73-2P 189059-74-3P  
 189059-75-4P 189059-76-5P 189059-77-6P  
 189059-78-7P 189059-99-2P 189060-04-6P  
 189060-05-7P 189060-07-9P 189060-10-4P  
 189060-13-7P 189060-16-0P 189060-33-1P  
 189060-37-5P 189060-45-5P 189060-48-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of arylbenzoxazepinones as hypolipemic agents)

RN 189058-77-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN	189058-80-8	CAPLUS
CN	D-Serine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)	

RN	189058-81-9	CAPLUS
CN	D-Threonine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-	

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-82-0 CAPLUS

CN L-Proline, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-83-1 CAPLUS

CN L-Proline, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-87-5 CAPLUS

CN L-Methionine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-89-7 CAPLUS

CN L-Serine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-90-0 CAPLUS

CN L-Asparagine, N2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-92-2 CAPLUS

CN L-Glutamine, N2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-93-3 CAPLUS

CN L-Threonine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189058-98-8 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, [3R-[trans(trans)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189058-99-9 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-01-6 CAPLUS

CN Benzeneacetic acid, 4-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-03-8 CAPLUS

CN L-Histidine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-04-9 CAPLUS

CN L-Tryptophan, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-08-3 CAPLUS

CN 4-Piperidinepentanoic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





Chemical structure of compound 10: A 3,4-dimethoxyphenyl group is connected via a dashed bond to a sulfur atom. The sulfur atom is part of a five-membered ring containing an oxygen atom and a carbonyl group. This ring is fused to a benzene ring with a chlorine atom at the 3-position and a 2-(4-(3-(carboxymethyl)phenyl)piperidin-1-yl)ethyl group at the 1-position. The piperidine ring is attached to a 3-(carboxymethyl)phenyl group.


RN	189059-11-8	CAPLUS
CN	4,1-Benzoxazepine-3-acetamide, N-(3-aminopropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R-trans)- (9CI) (CA INDEX NAME)	

● HCl

RN 189059-12-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[2-(4-morpholinyl)ethyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-13-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-piperidinyl)ethyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-14-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1-piperidinyl)propyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-15-2 CAPLUS

CN 1,4'-Bipiperidine, 1'-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 189059-16-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-N-[[4-(dimethylamino)phenyl]methyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-17-4 CAPLUS

CN 4-Piperidinamine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N,N-dimethyl-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-18-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[3-(3,4-dihydro-2(1H)-isoquinolinyl)propyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-20-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[3-(4-morpholinyl)propyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-21-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[3-(1-pyrrolidinyl)propyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-22-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(2-pyridinylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-23-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-24-3 CAPLUS

CN 4-Piperidinol, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-25-4 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, [3R-[3 $\alpha$ (R\*),5 $\beta$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-26-5 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, [3R-[3α(S\*),5β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-27-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[1-(hydroxymethyl)-3-methylbutyl]-2-oxo-, [3R-[3α(R\*),5β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-28-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-N-[1-(hydroxymethyl)-3-methylbutyl]-2-oxo-, [3R-[3 $\alpha$ (S\*),5 $\beta$ ]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-29-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(2-hydroxy-1-phenylethyl)-2-oxo-, [3R-[3 $\alpha$ (R\*),5 $\beta$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-30-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[1-(hydroxymethyl)-2-methylpropyl]-2-oxo-, [3R-[3 $\alpha$ (S\*),5 $\beta$ ]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 189059-31-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-32-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(3-hydroxypropyl)-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-33-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-N-(2-hydroxyethyl)-2-oxo-, (3R-trans)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-34-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[1-(hydroxymethyl)-2-phenylethyl]-2-oxo-, [3R-[3α(S\*),5β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-35-6 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(2-hydroxy-1-methylethyl)-2-oxo-, [3R-[3α(R\*),5β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-36-7 CAPLUS  
 CN Piperidine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4,4-dimethoxy-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-37-8 CAPLUS  
 CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189059-38-9 CAPLUS  
 CN 4-Piperidinone, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-39-0 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-[[4-(aminosulfonyl)phenyl]methyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-41-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-43-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[2-methyl-6-(1-methylethyl)phenyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-44-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-(2,4-difluorophenyl)-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-45-8 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-2-propenyl-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-46-9 CAPLUS  
 CN Morpholine, 4-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-47-0 CAPLUS  
 CN Piperidine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 189059-48-1 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N,N-dimethyl-2-oxo-, (3R-trans)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-49-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(1H-tetrazol-5-ylmethyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-50-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-1H-tetrazol-5-yl-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-56-1 CAPLUS

CN Piperidine, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-

1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-(1H-tetrazol-5-yl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-70-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-73-2 CAPLUS

CN Acetic acid, [1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyldene]-, (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 189059-74-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-75-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-76-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-77-6 CAPLUS

CN 4-Piperidineacetamide, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-(methylsulfonyl)-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-78-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-99-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[[1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-piperidinyl]methyl]phosphinylidene]bis(oxymethylene) ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-04-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-05-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[[ (3R,5S)-1-[3-(acetyloxy)-2-  
[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 189060-07-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-  
methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-  
(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-10-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-  
7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-  
3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-16-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-hydroxy-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-33-1 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-45-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-48-8 CAPLUS


CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1995:994196 CAPLUS Full-text  
 DN 124:55994  
 TI Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors  
 IN Yukimasa, Hidefumi; Tozawa, Ryuichi; Kori, Masakuni; Kitano, Kazuaki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 41 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9521834	A1	19950817	WO 1995-JP148	19950206
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	RU 2170732	C2	20010720	RU 1999-118298	19930419
	AU 9515898	A	19950829	AU 1995-15898	19950206
	JP 07267939	A	19951017	JP 1995-18972	19950207
	IN 1995CA00260	A	20050304	IN 1995-CA260	19950310
	BR 9501469	A	19970819	BR 1995-1469	19950406
PRAI	JP 1994-15531	A	19940209		
	WO 1995-JP148	A	19950206		
OS	MARPAT 124:55994				
GI					



I



II

AB Optically active 4,1-benzoxazepin-2-one derivs. I with (3R-trans)-configuration are disclosed [wherein R1 = alkyl; X = H or metal ion; ring A is substituted with halo; ring B is substituted with alkoxy]. I are useful for the prophylaxis or treatment of hypercholesteremia or coronary sclerosis in mammals. For example racemic trans-II was amidated with H-Ala-OBu-tert.HCl, and the resultant diastereomeric amides were separated by chromatog., deprotected, and hydrolyzed in acid and base, to give both the desired isomer (3R,5S)-II (A) and its enantiomer (3S,5R)-II (B). In an assay for inhibition of human hepatic squalene synthase in vitro, isomer A had IC50 of 0.011  $\mu$ M, vs. 0.020  $\mu$ M for its 2-chlorophenyl analog [known from EP 567026]. In a rat



enzyme system, the IC<sub>50</sub> of isomer A was 0.026  $\mu$ M, whereas isomer B only gave 43% inhibition at 10<sup>-5</sup> M.


IT 171768-62-0P 171768-63-1P 171768-64-2P  
171768-74-4P 171868-45-4P 171868-46-5P  
171868-47-6P 171868-48-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of optically active 4,1-benzoxazepine derivs. as squalene synthase inhibitors)

RN 171768-62-0 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171768-63-1 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171768-64-2 CAPLUS

CN L-Leucine, N-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171768-74-4 CAPLUS

CN L-Alanine, N-[[7-chloro-1-(2,2-dimethylpropyl)-5-(4-ethoxy-2-methoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171868-45-4 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171868-46-5 CAPLUS

CN L-Alanine, N-[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171868-47-6 CAPLUS

CN L-Leucine, N-[[7-chloro-5-(2,4-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171868-48-7 CAPLUS

CN L-Alanine, N-[[7-chloro-1-(2,2-dimethylpropyl)-5-(4-ethoxy-2-methoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:561116 CAPLUS Full-text  
 DN 146:493555  
 TI Use of TAK-475 together with ezetimibe for treating hyperlipidemia  
 IN Nishimoto, Tomoyuki; Iino, Hiroko; Wada, Takeo  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 20pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007058335	A1	20070524	WO 2006-JP323058	20061114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-736319P	P	20051115		
AB	A pharmaceutical composition useful for a prevention and/or treatment of hyperlipidemia, which comprises combining an effective amount of Compound X and ezetimibe is provided.				
IT	189060-13-7, TAK-475				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (use of TAK-475 together with ezetimibe for treating hyperlipidemia)				
RN	189060-13-7 CAPLUS				
CN	4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2- dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo- 4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)				


Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:538026 CAPLUS Full-text  
 DN 147:9956  
 TI Preparation of tricyclic compounds such as pyrrolobenzoxazepine derivatives and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis  
 IN Sugita, Kazuyuki; Otsuka, Masami; Oki, Hitoshi; Haginoya, Noriyasu; Ichikawa, Masanori; Itoh, Masao  
 PA Daiichi Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 1709pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007055093	A1	20070518	WO 2006-JP321056	20061023
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2005-306663	A	20051021		
OS	MARPAT 147:9956				
GI					




AB The title compds. I [R1 = aryl or heteroaryl which may have 1 to 3 substituents; R2, R2a = H, halo, cyano, etc.; R3 = H, halo, alkyl, etc.; R4 = carboxyl, carboxycarbonyl, carboxyalkenyl, etc.; X = CH2, O, S; Y = N, CR3a; R3a = same as defined for R3; Z = N, CR3aa; R3aa = same as defined for R3; ring (N) = benzene or pyridine ring] are prepared I inhibit squalene synthetase and cholesterol synthesis. Thus, 2-(2-(2-[(4R,6S)-8-chloro-6-(2,3-dimethoxyphenyl)-10-fluoro-4H,6H-pyrrolo[1,2-a][4,1]benzoxazepin-4-yl]ethyl)-2H-1,2,3,4-tetrazol-5-yl)acetic acid was prepared in a multistep process starting from 2-bromo-4-chloro-6-fluoroaniline and 2,5-dimethoxytetrahydrofuran. Compds. of this invention showed IC50 values of 0.56 nM to 7.6 nM against rat squalene synthetase.

IT 937062-98-1P 937062-99-2P 937064-07-8P  
 937064-08-9P 937064-12-5P 937064-14-7P  
 937064-18-1P 937064-19-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of tricyclic compds. such as pyrrolobenzoxazepine derivs. and analogs thereof for treatment of hypercholesteremia, hyperlipemia, and arteriosclerosis)


RN 937062-98-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.




RN 937062-99-2 CAPLUS  
CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 937064-07-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Relative stereochemistry.



RN 937064-08-9 CAPLUS

CN 5-Oxazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937064-12-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 937064-14-7 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 937064-18-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.






RN 937064-19-2 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[(2,4-dimethoxyphenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-4-methyl-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1286352 CAPLUS Full-text  
 DN 146:33131  
 TI Novel method of treating hyperlipidemia using a squalene synthase inhibitor and an HMG-CoA reductase inhibitor  
 IN Nishimoto, Tomoyuki; Tozawa, Ryuichi; Wada, Takeo; Ishikawa, Eiichiro; Nishi, Toshiya; Iino, Hiroko  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 141pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2006129859	A2	20061207	WO 2006-JP311362	20060531
	WO 2006129859	A3	20070419		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2005-685871P P 20050601  
 US 2005-728329P P 20051020

OS MARPAT 146:33131

AB A pharmaceutical composition useful for a prevention and/or treatment of hyperlipidemia, which comprises combining an effective amount of squalene synthase inhibitor and HMG-CoA reductase inhibitor is provided. Thus, plasma triglycerides of Wistar Fatty rats were lowered by treatment with squalene synthase inhibitor N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid (Compound X, 30 mg/kg) or HMG-CoA reductase inhibitor atorvastatin (30 mg/kg) from 519.7 mg/dL (vehicle) to 376.5 mg/dL for Compound X and 192.1 mg/dL for atorvastatin. By use in combination of Compound X and atorvastatin, an addnl. action of lowering plasma triglyceride was observed (142.9 mg/dL).

IT 189060-13-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comps. comprising squalene synthase inhibitor and HMG-CoA reductase inhibitor for prevention and/or treatment of hyperlipidemia with reduced toxicity)

RN 189060-13-7 CAPLUS


CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1224848 CAPLUS Full-text  
 DN 146:134491  
 TI Chemical Database Mining through Entropy-Based Molecular Similarity  
 Assessment of Randomly Generated Structural Fragment Populations  
 AU Batista, Jose; Bajorath, Juergen  
 CS Department of Life Science Informatics, Rheinische Friedrich-Wilhelms-  
 Universitaet, Bonn, D-53113, Germany  
 SO Journal of Chemical Information and Modeling (2007), 47(1), 59-68  
 CODEN: JCISD8; ISSN: 1549-9596  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB The authors describe a novel approach to search for active compds. that is  
 based on the generation of random mol. fragment populations. As a similarity-  
 based methodol., fragment profiling does not depend on the use of predefined  
 descriptors of mol. structure and properties and the design of chemical space  
 representations. To adapt the generation and comparison of random fragment  
 populations for large-scale compound screening, the authors compare different  
 fragmentation schemes, introduce the concept of compound class-specific  
 fragment frequencies, and develop a novel entropic similarity metric for  
 compound ranking. The approach has been extensively tested on 15 different  
 compound activity classes with varying degrees of intraclass structural  
 diversity and produced promising results in these calcns., comparable to  
 similarity searching using fingerprints. A key feature of fragment profile  
 searching is that the calcn. of compound class-specific proportional Shannon  
 entropy of random fragment distributions enables the identification of  
 database mols. that share a significant number of signature substructures with  
 known active compds.  
 IT 606928-75-0  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (chemical database mining through entropy-based mol. similarity  
 assessment)  
 RN 606928-75-0 CAPLUS  
 CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-  
 3-[2-(3,4-dihydro-1(2H)-pyridinyl)-2-oxoethyl]-5-(2,3-dimethoxyphenyl)-1,5-  
 dihydro-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1147695 CAPLUS Full-text  
 DN 145:465761  
 TI Remedy for xanthoma containing squalene synthetase inhibitor  
 IN Shiomi, Masashi; Ito, Takashi; Tozawa, Ryuichi; Amano, Yuichiro  
 PA National University Corporation Kobe University, Japan; Takeda  
 Pharmaceutical Company Limited  
 SO PCT Int. Appl., 102pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006115193	A1	20061102	WO 2006-JP308402	20060421
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI JP 2005-124781 A 20050422

OS MARPAT 145:465761

AB Disclosed is a preventive/remedy for xanthoma which contains a compound having an inhibitory effect on squalene synthase, its prodrug or its salt. For example, the effect of N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid (I) on xanthoma in rabbits was examined. Also, a capsule containing I 10 mg/capsule was formulated.

IT 189060-13-7 839723-32-9 839723-37-4  
 839724-23-1 839724-36-6 839725-28-9  
 839725-30-3 913621-84-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(remedies for xanthoma containing squalene synthetase inhibitors)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-32-9 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-37-4 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-23-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-36-6 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-28-9 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-30-3 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913621-84-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1039683 CAPLUS Full-text  
 DN 146:92343  
 TI Drug evaluation: TAK-475 - an oral inhibitor of squalene synthase for hyperlipidemia  
 AU Burnett, John R.  
 CS Department of Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, WA, 6847, Australia  
 SO Current Opinion in Investigational Drugs (Thomson Scientific) (2006), 7(9), 850-856  
 CODEN: COIDAZ; ISSN: 1472-4472  
 PB Thomson Scientific  
 DT Journal; General Review  
 LA English  
 AB A review. Takeda Pharmaceutical Co Ltd is developing TAK-475, a squalene synthetase inhibitor from a series of 4,1-benzoxazepine-3-acetic acid derivs., for the potential oral treatment of hyperlipidemia. By Mar. 2005, TAK-475 was undergoing phase III clin. trials in the US and Europe.  
 IT 189060-13-7P, TAK-475  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (TAK-475, squalene synthase inhibitor may be used in treatment of hyperlipidemia in patient)  
 RN 189060-13-7 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:147713 CAPLUS Full-text  
 DN 144:219288  
 TI Benzoxazepinylacetyl piperidineacetic acid derivative as C-reactive protein lowering agent  
 IN Imura, Yoshimi; Tozawa, Ryuichi; Nishimoto, Tomoyuki  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 129 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006016681	A2	20060216	WO 2005-JP14863	20050808
	WO 2006016681	A3	20060330		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2575014 A1 20060216 CA 2005-2575014 20050808 EP 1776096 A2 20070425 EP 2005-770555 20050808 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR PRAI JP 2004-232605 A 20040809 WO 2005-JP14863 W 20050808 OS MARPAT 144:219288 GI				




I

AB The present invention provides a novel drug which is useful as a preventive and/or therapeutic agent for various diseases involved in elevation of C-reactive protein (CRP) level, in particular, inflammatory disease and cancer comprising a compound having inhibitory activity against squalene synthase or a salt thereof, or a prodrug thereof. Capsules and tablets were prepared containing I. The squalene synthase inhibitor I decreased the CRP concentration in plasma of rats.


IT 189060-13-7  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (benzoxazepinylacetyl piperidineacetic acid derivative as C-reactive  
 protein lowering agent)  
 RN 189060-13-7 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-  
 dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-  
 4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 189059-71-0  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (benzoxazepinylacetyl piperidineacetic acid derivative as C-reactive  
 protein lowering agent)  
 RN 189059-71-0 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
 1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
 3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1328544 CAPLUS Full-text  
 DN 144:69867  
 TI Preparation of aliphatic cyclic carboxamide having carboxyl group by highly selective novel amidation without protection of carboxyl group  
 IN Inagaki, Atsushi; Sera, Misayo  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005121133	A1	20051222	WO 2005-JP11091	20050610
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005252111	A1	20051222	AU 2005-252111	20050610
	CA 2569686	A1	20051222	CA 2005-2569686	20050610
	EP 1753752	A1	20070221	EP 2005-751255	20050610
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	IN 2006KN03429	A	20070615	IN 2006-KN3429	20061120
	NO 2007000123	A	20070307	NO 2007-123	20070108
PRAI	JP 2004-174417	A	20040611		
	WO 2005-JP11091	W	20050610		
OS	CASREACT 144:69867; MARPAT 144:69867				
GI					



I



AB The present invention provides an industrial production method with a short process having a high yield of an aliphatic cyclic carboxamide having carboxyl group. The process comprises reacting functional group-selectively using an

inexpensive condensing agent without protecting the carboxyl group by esterification, i.e., reacting carboxylic acid anhydride obtained by reacting carboxylic acid and tertiary carboxylic acid halide with aliphatic cyclic secondary amine having carboxyl group. Thus, 23.0 kg [(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-acetoxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetic acid (I) (R = OH) and 4.6 kg Et<sub>3</sub>N were added to 138 L MeCN, and 5.8 kg pivaloyl chloride was added thereto at about 0°. After reacting at 0-5° for 1 h, 9.7 kg piperidine-4-acetic acid hydrochloride and 6.7 kg Et<sub>3</sub>N were added at the same temperature. The resulting mixture was stirred at 20-28° for 30 min and treated with 0.5 N HCl (46 L) and 184 L Et acetate and the layers were separated. The organic layer was washed with 3% brine (46 L x 2), concentrated under reduced pressure to total volume of 140 L, treated with 92 L n-heptane at 75° to 55°, cooled to .apprx.5°, and stirred to mature for 1 h. The precipitated crystals were collected by filtration, and dried under reduced pressure to give 26.0 kg I (R = O), namely [1-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid (II) (88.4% yield). II is useful for preventing and/or treating hyperlipidemia, familial hypercholesterolemia, organ failure or organ dysfunction and a method for protecting skeletal muscle. Various pharmaceutical formulations containing II were described.

IT 189060-13-7P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carboxy-containing aliphatic cyclic carboxamide by highly selective amidation of carboxylic acid with carboxy-containing aliphatic cyclic secondary amine via carboxylic acid anhydride without carboxy protection)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD.  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:638758 CAPLUS Full-text  
 DN 143:139213  
 TI Method of improving suitability for granulation  
 IN Murakawa, Yusuke; Fukuta, Makoto  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 27 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005065715	A1	20050721	WO 2004-JP19767	20041224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1698349	A1	20060906	EP 2004-808117	20041224
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	US 2007122471	A1	20070531	US 2006-584242	20060623
PRAI	JP 2003-430169	A	20031225		
	WO 2004-JP19767	W	20041224		

AB Disclosed are granules which comprise a compound having poor wettability and a surfactant, especially ones at least about 35 weight% of which do not pass through a Number 100 screen. Also provided is a process for producing granules containing a compound with poor wettability and having improved suitability for granulation, the process comprising adding a surfactant to the compound before or during granulation especially in such an amount that the weight ratio of the surfactant to the compound is from about 0.001 to about 2.


IT 383652-98-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (surfactants for improving granulation of drugs with poor wettability)

RN 383652-98-0 CAPLUS


CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:120907 CAPLUS Full-text  
 DN 142:219318  
 TI Preparation of benzoxazepine derivatives as squalene synthase inhibitors  
 IN Marui, Shogo; Miki, Takashi; Miura, Shoutarou; Nishimoto, Tomoyuki;  
 Nakada, Yoshihisa  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 239 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012272	A1	20050210	WO 2004-JP11293	20040730
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004260757	A1	20050210	AU 2004-260757	20040730
	CA 2534464	A1	20050210	CA 2004-2534464	20040730
	JP 2005068138	A	20050317	JP 2004-222658	20040730
	EP 1650201	A1	20060426	EP 2004-748264	20040730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1832934	A	20060913	CN 2004-80022202	20040730
	BR 2004013009	A	20061003	BR 2004-13009	20040730
	NO 2006001009	A	20060502	NO 2006-1009	20060301
PRAI	JP 2003-285341	A	20030801		
	WO 2004-JP11293	W	20040730		
OS	MARPAT 142:219318				
GI					



I

AB The title compds. I (ring A and ring B each represents an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R1 represents a lower alkyl optionally substituted by optionally substituted hydroxy; X1a represents a bond or optionally substituted lower alkylene; X1b represents a bond or optionally substituted lower alkylene; X2 represents a bond, O, or S; X3 represents a bond or an optionally substituted divalent hydrocarbon group; and Y represents optionally esterified or amidated carboxy) are prepared A process for preparing I is disclosed. Thus, (2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]methyl]-

1,3-thiazol-5-yl)acetic acid was prepared in a multistep process from 2-(tert-butoxycarbonylamino)acetic acid and potassium monoethyl malonate. Compds. of this invention are said to show IC50 values of  $\leq 1 \mu\text{M}$  against squalene synthase. Formulations are given.

IT 839723-04-5P 839723-05-6P 839723-06-7P  
839723-07-8P 839723-08-9P 839723-09-0P  
839723-10-3P 839723-11-4P 839723-12-5P  
839723-13-6P 839723-14-7P 839723-15-8P  
839723-16-9P 839723-17-0P 839723-18-1P  
839723-19-2P 839723-20-5P 839723-21-6P  
839723-22-7P 839723-23-8P 839723-24-9P  
839723-25-0P 839723-26-1P 839723-27-2P  
839723-28-3P 839723-29-4P 839723-30-7P  
839723-31-8P 839723-32-9P 839723-33-0P  
839723-34-1P 839723-35-2P 839723-36-3P  
839723-37-4P 839723-38-5P 839723-39-6P  
839723-40-9P 839723-41-0P 839723-42-1P  
839723-43-2P 839723-44-3P 839723-45-4P  
839723-46-5P 839723-47-6P 839723-48-7P  
839723-49-8P 839723-50-1P 839723-51-2P  
839723-52-3P 839723-53-4P 839723-54-5P  
839723-55-6P 839723-56-7P 839723-57-8P  
839723-58-9P 839723-59-0P 839723-60-3P  
839723-61-4P 839723-62-5P 839723-63-6P  
839723-64-7P 839723-65-8P 839723-66-9P  
839723-67-0P 839723-68-1P 839723-69-2P  
839723-70-5P 839723-71-6P 839723-72-7P  
839723-88-5P 839723-89-6P 839723-90-9P  
839723-91-0P 839723-92-1P 839723-93-2P  
839723-94-3P 839723-95-4P 839723-96-5P  
839723-97-6P 839723-98-7P 839723-99-8P  
839724-00-4P 839724-01-5P 839724-02-6P  
839724-03-7P 839724-04-8P 839724-05-9P  
839724-06-0P 839724-07-1P 839724-08-2P  
839724-09-3P 839724-10-6P 839724-11-7P  
839724-12-8P 839724-13-9P 839724-14-0P  
839724-15-1P 839724-16-2P 839724-17-3P  
839724-18-4P 839724-19-5P 839724-20-8P  
839724-21-9P 839724-22-0P 839724-23-1P  
839724-24-2P 839724-25-3P 839724-26-4P  
839724-27-5P 839724-28-6P 839724-29-7P  
839724-30-0P 839724-31-1P 839724-32-2P  
839724-33-3P 839724-34-4P 839724-35-5P  
839724-36-6P 839724-37-7P 839724-38-8P  
839724-39-9P 839724-40-2P 839724-41-3P  
839724-42-4P 839724-43-5P 839724-44-6P  
839724-45-7P 839724-46-8P 839724-47-9P  
839724-48-0P 839724-49-1P 839724-50-4P  
839725-25-6P 839725-26-7P 839725-27-8P  
839725-28-9P 839725-29-0P 839725-30-3P  
839725-31-4P 839725-32-5P 839725-33-6P  
839725-34-7P 839725-35-8P 839725-36-9P  
839725-37-0P 839725-38-1P 839725-39-2P  
839725-40-5P 839725-41-6P 839725-42-7P  
840494-05-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzoxazepine derivs. as squalene synthase inhibitors)

RN 839723-04-5 CAPLUS



CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-05-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-06-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-07-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-08-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-09-0 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-10-3 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-11-4 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[[1-(hydroxymethyl)cyclobutyl]methyl]-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-12-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[[1-(hydroxymethyl)cyclobutyl]methyl]-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-13-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-propyl-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-14-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-15-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-ethyl-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-16-9 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-

1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-17-0 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-18-1 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-19-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-20-5 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-methoxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-21-6 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\beta$ -hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-22-7 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-thiazolyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 839723-23-8 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839723-24-9 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-25-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-26-1 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-27-2 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-28-3 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-thiazolyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-29-4 CAPLUS

CN 5-Thiazolecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-30-7 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, calcium salt (1:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Ca

RN 839723-31-8 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl-, calcium salt (1:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Ca

RN 839723-32-9 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl-, calcium salt (1:1) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-33-0 CAPLUS

CN 5-Oxazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-34-1 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-35-2 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-36-3 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-37-4 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-38-5 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-1-propyl-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-39-6 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-ethyl-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-40-9 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-

tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-41-0 CAPLUS

CN 4-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-42-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839723-43-2 CAPLUS

CN 1H-Pyrazole-1-butanoic acid, 4-carboxy-3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-44-3 CAPLUS

CN 1H-Pyrazole-1-butanoic acid, 4-carboxy-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-45-4 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-carboxy-3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-46-5 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-carboxy-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-47-6 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1-(2-carboxyphenyl)-, 4-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-48-7 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1-(3-carboxyphenyl)-, 4-ethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 839723-49-8 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1-(4-carboxyphenyl)-, 4-ethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 839723-50-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(2-carboxyphenyl)-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-51-2 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(3-carboxyphenyl)-5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-52-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-(4-carboxyphenyl)-5-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-53-4 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-54-5 CAPLUS

CN 2-Propenoic acid, 3-[1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-1H-pyrazol-5-yl]-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 839723-55-6 CAPLUS

CN 1H-Imidazole-5-carboxylic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-56-7 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-57-8 CAPLUS

CN 1,3,4-Oxadiazole-2-acetic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-58-9 CAPLUS

CN 1,3,4-Thiadiazole-2-acetic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-59-0 CAPLUS

CN 1,3,4-Thiadiazole-2-propanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX .NAME)


Absolute stereochemistry.



RN 839723-60-3 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839723-61-4 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-62-5 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-63-6 CAPLUS

CN 1,2,4-Oxadiazole-5-acetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-64-7 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-65-8 CAPLUS

CN 1H-1,2,4-Triazole-3-acetic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-66-9 CAPLUS

CN Benzoic acid, 3-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-67-0 CAPLUS

CN Benzoic acid, 3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-68-1 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-69-2 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-70-5 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-ethoxy-1H-pyrazol-1-yl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-71-6 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-72-7 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 5-(carboxymethoxy)-3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-88-5 CAPLUS

CN 3-Furancarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-89-6 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-90-9 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-91-0 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-92-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-93-2 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 1-[2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-94-3 CAPLUS

CN 1H-Pyrazole-4-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-95-4 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839723-96-5 CAPLUS

CN 1H-Pyrazole-3-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- $\beta$ -hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839723-97-6 CAPLUS

CN 1H-Pyrazole-5-propanoic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- $\beta$ -hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839723-98-7 CAPLUS

CN 2-Propenoic acid, 3-[1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-1H-pyrazol-4-yl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839723-99-8 CAPLUS

CN 1,3,4-Thiadiazole-2-butanoic acid, 5-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-00-4 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-α-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-01-5 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-02-6 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 1/2 Ca

RN 839724-03-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -(phenylmethylene)-, ( $\alpha$ Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-04-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -hydroxy-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-05-9 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\beta,\beta$ -dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-06-0 CAPLUS

CN 5-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-07-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-08-2 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-09-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-10-6 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-11-7 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-12-8 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-β-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-13-9 CAPLUS

CN 2-Propenoic acid, 3-[2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-4-thiazolyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-14-0 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-15-1 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- $\beta,\beta$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839724-16-2 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-17-3 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-18-4 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-19-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-20-8 CAPLUS

CN 2-Thiopheneacetic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-21-9 CAPLUS

CN 5-Thiazolecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-22-0 CAPLUS

CN 5-Thiazoleacetic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-23-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-24-2 CAPLUS

CN 4-Thiazoleacetic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-25-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-26-4 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-27-5 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-28-6 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-29-7 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-30-0 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-31-1 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl]- (9CI) (CA INDEX NAME)

1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-32-2 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-33-3 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-34-4 CAPLUS

CN 4-Oxazolepropanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-35-5 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-36-6 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839724-37-7 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-38-8 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-39-9 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[2-[(3R,5S)-7-chloro-5-(2,3-

·dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-40-2 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-41-3 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-42-4 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-43-5 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-methyl-, (βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-44-6 CAPLUS

CN Acetic acid, [[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-45-7 CAPLUS

CN Propanoic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]-2-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-46-8 CAPLUS

CN Acetic acid, [[1-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]-1-methylethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-47-9 CAPLUS

CN Acetic acid, [[1-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]-1-methylethyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-48-0 CAPLUS

CN Acetic acid, [[1-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-49-1 CAPLUS

CN Propanoic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl]thio]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-50-4 CAPLUS

CN Acetic acid, [[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-25-6 CAPLUS

CN Propanoic acid, 2-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-26-7 CAPLUS

CN Butanoic acid, 4-[[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-27-8 CAPLUS

CN Acetic acid, [[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-28-9 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-29-0 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-30-3 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839725-31-4 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-32-5 CAPLUS

CN 1,2,4-Oxadiazole-5-butanoic acid, 3-[3-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-33-6 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-34-7 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-35-8 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-36-9 CAPLUS

CN 1,3,4-Oxadiazole-2-butanoic acid, 5-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA-INDEX NAME)


Absolute stereochemistry.



RN 839725-37-0 CAPLUS


CN 1,3,4-Oxadiazole-2-propanoic acid, 5-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA-INDEX NAME)

Absolute stereochemistry.




RN 839725-38-1 CAPLUS  
 CN 5-Thiazolepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\beta$ -hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-39-2 CAPLUS  
 CN 2-Propenoic acid, 3-[4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-thiazolyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 839725-40-5 CAPLUS  
 CN 5-Thiazolepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-41-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-42-7 CAPLUS

CN 2-Thiophenebutanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 840494-05-5 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 839725-23-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzoxazepine derivs. as squalene synthase inhibitors)

RN 839725-23-4 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-3-[[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]methyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 189059-52-7P 839724-51-5P 839724-52-6P  
839724-54-8P 839724-57-1P 839724-58-2P  
839724-60-6P 839724-61-7P 839724-62-8P  
839724-63-9P 839724-64-0P 839724-65-1P  
839724-66-2P 839724-67-3P 839724-68-4P  
839724-70-8P 839724-71-9P 839724-72-0P  
839724-73-1P 839724-74-2P 839724-75-3P  
839724-76-4P 839724-78-6P 839724-79-7P  
839724-80-0P 839724-81-1P 839724-82-2P  
839724-83-3P 839724-84-4P 839724-85-5P  
839724-86-6P 839724-87-7P 839724-88-8P  
839724-95-7P 839724-96-8P 839724-97-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

RN 189059-52-7 CAPLUS

Absolute stereochemistry.




CN Butanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

CCOC(=O)CCC(=O)NC(=O)CC1OC2SC3C(=O)N(C(C)(C)COC(=O)C)C4=CC=C(C=C4C5=CC=C(C=C5)OC)C3=C2C1=O

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-54-8 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-57-1 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839724-58-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 839724-60-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-61-7 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-62-8 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-63-9 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-β-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839724-64-0 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-thiazolyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839724-65-1 CAPLUS

CN Hexanoic acid, 4-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5-oxo-, methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-66-2 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-67-3 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-68-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-70-8 CAPLUS

CN 5-Thiazolecarboxylic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-71-9 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-72-0 CAPLUS

CN 5-Oxazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-73-1 CAPLUS

CN 5-Oxazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-74-2 CAPLUS

CN 4-Oxazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-75-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-76-4 CAPLUS

CN 1H-Pyrazole-1-butanoic acid, 3-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-4-(ethoxycarbonyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-78-6 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[2-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-79-7 CAPLUS

CN 1H-Pyrazole-3-acetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-80-0 CAPLUS

CN Propanedioic acid, monoethyl ester, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839724-81-1 CAPLUS

CN 1,3,4-Oxadiazole-2-acetic acid, 5-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-82-2 CAPLUS

CN 1,3,4-Thiadiazole-2-acetic acid, 5-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-83-3 CAPLUS

CN Butanedioic acid, monoethyl ester, 2-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-84-4 CAPLUS

CN 1,3,4-Thiadiazole-2-propanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-85-5 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-3-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl]-5-(2,3-dimethoxyphenyl)-1,5-dihydro-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-86-6 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-87-7 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-ethoxy-1H-pyrazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-88-8 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-5-hydroxy-1H-pyrazol-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-95-7 CAPLUS

CN 4-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839724-96-8 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-  
[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-  
tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -(phenylmethyl)-,  
ethyl ester (9CI) (CA INDEX NAME)

CN 5-Thiazoleacetic acid, 2-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-  
[[ (1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-  
tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -  
(hydroxyphenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry..




RN 839725-00-7 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- $\alpha$ -(phenylmethylene)-, ethyl ester, ( $\alpha$ Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 839725-04-1 CAPLUS

CN 4-Thiazolepropanenitrile, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- $\alpha$ [[[(1,1-dimethylethyl)dimethylsilyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-06-3 CAPLUS

CN 4-Thiazoleacetic acid, 2-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]-1-hydroxyethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-07-4 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-12-1 CAPLUS

CN 1,2,4-Oxadiazole-5-acetonitrile, 3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-14-3 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-15-4 CAPLUS

CN Ethanethioic acid, O-[[3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-oxadiazol-5-yl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 839725-16-5 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-3-[(5-chloro-1,2,4-thiadiazol-3-yl)methyl]-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,5-dihydro-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-17-6 CAPLUS

CN Acetic acid, [[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-1,2,4-thiadiazol-5-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 839725-43-8 CAPLUS

CN Propanoic acid, 2-[[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl)methyl]-  
1,2,4-thiadiazol-5-yl]thio]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-44-9 CAPLUS

CN 1,2,4-Oxadiazole-5-pentanoic acid, 3-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-47-2 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]-1-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-48-3 CAPLUS

CN 1,2,4-Oxadiazole-5-propanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 839725-49-4 CAPLUS

CN 1,3,4-Oxadiazole-2-propanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:902194 CAPLUS Full-text  
 DN 141:395590  
 TI Preparation of benzoxazepine compounds as RFRP receptor antagonists  
 IN Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Mabuchi, Hiroshi; Yoshida, Hiromi; Matsumoto, Hirokazu; Wakabayashi, Takeshi  
 PA Takeda Chemical Industries Ltd., Japan  
 SO PCT Int. Appl., 226 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091628	A1	20041028	WO 2004-JP5406	20040415
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004331659	A	20041125	JP 2004-120246	20040415
	EP 1623710	A1	20060208	EP 2004-727766	20040415
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 2007129348	A1	20070607	US 2005-553273	20051012
PRAI	JP 2003-114313	A	20030418		
	WO 2004-JP5406	W	20040415		
OS	MARPAT 141:395590				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. I [A = (un)substituted aromatic ring; B = (un)substituted benzene ring; X = O, S(:O)n, NR<sub>3</sub>; n = 0-2; R<sub>3</sub> = H, (un)substituted hydrocarbon group, etc.; R<sub>1</sub>, R<sub>2</sub> = H, (un)substituted hydrocarbon group, etc.] were prepared. For example, reductive amination of compound trans-II·HCl [Q = H] with 3-phenylpropanaldehyde afforded compound trans-II·HCl [Q = 3-phenylpropyl]. In human RFRP-3 (RFamide-related peptide-3) binding inhibition assays, the IC<sub>50</sub> value was <1 μM. Compds. I are claimed useful as analgesics, prolactin secretion regulators, etc. Formulations are given.

IT 782466-03-9P 782466-05-1P 782466-07-3P  
 782466-49-3P 782466-51-7P 782466-55-1P  
 782466-61-9P 782467-32-7P 782467-34-9P  
 782467-38-3P 782467-40-7P 782468-11-5P  
 782468-62-6P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782466-03-9 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-05-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-07-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-49-3 CAPLUS

CN Carbamic acid, [2-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]ethyl]-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-51-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-aminoethoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-55-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(3-phenylpropyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-61-9 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl](3-phenylpropyl)-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-32-7 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-3-[2-[[[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 782467-34-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 782467-38-3 CAPLUS

CN Carbamic acid, [3-[3-[(3R,5S)-7-chloro-3-[2-[[2-(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-1-methyl-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]propyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-40-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(3-aminopropoxy)-2-methoxyphenyl]-7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-1-methyl-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782468-11-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-62-6 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 782466-09-5P 782466-11-9P 782466-13-1P  
 782466-15-3P 782466-17-5P 782466-19-7P  
 782466-21-1P 782466-23-3P 782466-25-5P  
 782466-27-7P 782466-29-9P 782466-31-3P  
 782466-33-5P 782466-35-7P 782466-37-9P  
 782466-39-1P 782466-41-5P 782466-43-7P  
 782466-45-9P 782466-47-1P 782466-53-9P  
 782466-57-3P 782466-59-5P 782466-81-3P  
 782466-83-5P 782466-85-7P 782466-87-9P  
 782466-89-1P 782466-91-5P 782466-93-7P  
 782466-95-9P 782466-97-1P 782466-99-3P  
 782467-01-0P 782467-03-2P 782467-05-4P  
 782467-07-6P 782467-09-8P 782467-11-2P  
 782467-13-4P 782467-15-6P 782467-17-8P  
 782467-19-0P 782467-21-4P 782467-23-6P  
 782467-25-8P 782467-28-1P 782467-30-5P  
 782467-36-1P 782467-42-9P 782467-53-2P  
 782467-63-4P 782467-69-0P 782467-73-6P  
 782467-75-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 782466-09-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(pentylamino)propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI)  
 (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-11-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(phenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-13-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-5-[3-[3-[(2-furanylmethyl)amino]propoxy]-2-methoxyphenyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-15-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-thienylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-17-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-pyridinylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-19-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-naphthalenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-21-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(1-naphthalenylmethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-23-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(4-phenylbutyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-25-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(4-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-27-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(3-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-29-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-31-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

RN 782466-33-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenoxylethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-35-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenylethyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782466-37-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2E)-3-phenyl-2-propenyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
Double bond geometry as shown.



RN 782466-39-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[[3-(4-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

—OMe

RN 782466-41-5 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[[3-(3-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

— OMe

RN 782466-43-7 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[[3-(2-methoxyphenyl)propyl]amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-45-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(3,4-dimethoxyphenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




● HCl

— OMe

RN 782466-47-1 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[3-[[2-(1H-indol-3-yl)ethyl]amino]propoxy]-2-methoxyphenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

PAGE 1-A



PAGE 1-B.


● HCl



RN 782466-53-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(2-phenylethyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-57-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[(4-phenylbutyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-59-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-[methyl(3-phenylpropyl)amino]ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-81-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-83-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






● HCl

RN 782466-85-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(2-phenylethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-87-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-N-methyl-2-oxo-N-(phenylmethyl)-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-89-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-phenyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-91-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(2-pyridinylmethyl)-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782466-93-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-propyl-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-95-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N,N-diethyl-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-97-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methoxyphenyl)methyl]-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782466-99-3 CAPLUS

CN Piperidine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-01-0 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-03-2 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-4-methyl-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-05-4 CAPLUS

CN Morpholine, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-07-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(4-piperidinylmethyl)-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-09-8 CAPLUS

CN 1,4'-Bipiperidine, 1'--[[ (3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-11-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(2-aminoethyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-13-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(3-aminopropyl)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-15-6 CAPLUS

CN 4-Piperidinamine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.






● 2 HCl

RN 782467-17-8 CAPLUS

CN 1H-1,4-Diazepine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]hexahydro-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-19-0 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-1-(2,2-dimethylpropyl)-1,5-dihydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-3-[2-oxo-2-(4-piperidiny)ethyl]-, dihydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-21-4 CAPLUS

CN Glycine, N-[[ (3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-23-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-(dimethylamino)propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-25-8 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-28-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-2-oxo-, dihydrochloride, (3R,5S)-rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-30-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[2-(dimethylamino)ethoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-36-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-42-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-1-methyl-2-oxo-, monohydrochloride, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782467-53-2 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-63-4 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 782467-69-0 CAPLUS

CN Piperazine, 1-[[[(3R,5S)-7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]methyamino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 782467-73-6 CAPLUS

CN 4-Piperidinol, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 782467-75-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, dihydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



●2 HCl

IT 782468-96-6 782469-00-5 782469-02-7  
 782469-04-9 782469-06-1 782469-52-7  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (preparation of benzoxazepine compds. as agents for controlling function of  
 RFRP receptor)  
 RN 782468-96-6 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-  
 fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-  
 phenylpentyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX  
 NAME)


Relative stereochemistry.



RN 782469-00-5 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-  
 fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2E)-3-phenyl-  
 2-propenyl]amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX  
 NAME)

Relative stereochemistry.  
 Double bond geometry as shown.






RN 782469-02-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-N-propyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-04-9 CAPLUS

CN Piperidine, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-06-1 CAPLUS

CN 4-Piperidinol, 1-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(5-phenylpentyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782469-52-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[3-[[3-(2-chlorophenyl)propyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 737784-63-3P 737784-70-2P 782468-13-7P  
782468-15-9P 782468-17-1P 782468-27-3P  
782468-29-5P 782468-31-9P 782468-35-3P  
782468-37-5P 782468-58-0P 782468-60-4P  
782468-92-2P 782468-94-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxazepine compds. as agents for controlling function of RFRP receptor)

RN 737784-63-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-(3-hydroxy-2-methoxyphenyl)-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-70-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-13-7 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[methyl(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-15-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-nitrophenyl)sulfonyl](2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-17-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(2-phenoxyethyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-27-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-29-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-N-(phenylmethyl)-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-31-9 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-5-[2-methoxy-3-[3-[(3-phenylpropyl)amino]propoxy]phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-35-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-1-methyl-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-(3-hydroxy-2-methoxyphenyl)-1-methyl-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-58-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-[3-[3-[[[(1,1-dimethylethoxy)carbonyl](3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-60-4 CAPLUS

CN 1,2-Piperazinedicarboxylic acid, 4-[[ (3R,5S)-7-chloro-5-[3-[3-[[ (1,1-dimethylethoxy)carbonyl] (3-phenylpropyl)amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1-(1,1-dimethylethyl) 2-ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-92-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 782468-94-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-[(2,4-dimethoxyphenyl)methyl]-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-(3-hydroxy-2-methoxyphenyl)-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:648392 CAPLUS Full-text  
 DN 141:190808  
 TI Preparation of aromatic ring-fused cyclic compounds as TGR5 receptor agonists  
 IN Itoh, Fumio; Hinuma, Shuji; Kanzaki, Naoyuki; Miki, Takashi; Kawamata, Yuji; Oi, Satoru; Tawaraishi, Taisuke; Ishichi, Yuji; Hirohashi, Mariko  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 337 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004067008	A1	20040812	WO 2004-JP706	20040127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	CA 2514547	A1	20040812	CA 2004-2514547	20040127
	JP 2004346059	A	20041209	JP 2004-18643	20040127
	EP 1591120	A1	20051102	EP 2004-705536	20040127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006199795	A1	20060907	US 2005-543997	20051031
PRAI	JP 2003-19272	A	20030128		
	JP 2003-124311	A	20030428		
	WO 2004-JP706	W	20040127		
OS	MARPAT 141:190808				
GI					



AB It is intended to provide G protein-coupled receptor (TGR5) agonists containing fused ring compds. represented by the following general formula (I), salts or prodrugs thereof (wherein the ring A represents an optionally substituted aromatic ring; and the ring B represents a 5- to 8-membered ring having one or more substituents). Also disclosed are regulators for physiol. functions involving TGR5, preventives and/or remedies for various diseases involving TGR5, cytokine production inhibitors, GLP-1 secretion promoters, insulin secretion promoters, appetite depressants, pancreas regenerants, promoters for pancreas  $\beta$ -cell differentiation or proliferation, insulin resistance improvers, or immunosuppressants. containing the compds. I. In particular disclosed are preventives and/or remedies containing the compds. I for heart failure, myocardial infarction, acute kidney failure, angina pectoris, arrhythmia, bronchial asthma, chronic obstructive pulmonary disease, arteriosclerosis, chronic articular rheumatism, diabetes, obesity, insulin secretion failure, pancreas fatigue, gastric ulcer, ulcerative colitis, allergy, osteoarthritis, erythematodes, or excessive immune reaction after transplant surgery. The compds. I are also useful for screening ligands, agonists, or antagonists of TGR5. Thus, 0.1 g 2-[trans-7-chloro-5-(3-

formylphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]- N-(2-fluorobenzyl)acetamide was reduced by NaBH<sub>4</sub> in MeOH at room temperature for 30 min to give 76 mg 2-[trans-7-chloro-5-(3-hydroxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-N-(2-fluorobenzyl)acetamide (II).

II at 1  $\mu$ M increased the production of cAMP in CHO cells expressing human TGR5 by 128%. Pharmaceutical formulations containing specific compound I were also prepared

IT 737785-03-4P 737785-06-7P 737785-08-9P

737785-09-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists,

cytokine production inhibitors and appetite depressants)

RN 737785-03-4 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 5-[3-(2-amino-2-oxoethoxy)-2-methoxyphenyl]-7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737785-06-7 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[3-[2-(dimethylamino)-2-oxoethoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 737785-08-9 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-[2-oxo-2-[(2-phenylethyl)amino]ethoxy]phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 737785-09-0 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[3-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-2-oxoethoxy]-2-methoxyphenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 737784-63-3P 737784-70-2P 737784-72-4P  
 737784-73-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aromatic ring-fused cyclic compds. as TGR5 receptor agonists,


cytokine production inhibitors and appetite depressants)

RN 737784-63-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-

fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-(3-hydroxy-2-methoxyphenyl)-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-70-2 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-1-(2,2-dimethylpropyl)-N-[(2-fluorophenyl)methyl]-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-72-4 CAPLUS

CN Acetic acid, [3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 737784-73-5 CAPLUS

CN Acetic acid, [3-[(3R,5S)-7-chloro-1-(2,2-dimethylpropyl)-3-[2-[(2-fluorophenyl)methyl]amino]-2-oxoethyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-5-yl]-2-methoxyphenoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:633548 CAPLUS Full-text  
 DN 141:162403  
 TI Skeletal muscle protecting agents containing squalene synthase inhibitors  
 IN Tozawa, Ryuichi; Nishimoto, Tomoyuki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004064865	A1	20040805	WO 2004-JP234	20040115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	JP 2003277377	A	20031002	JP 2003-10125	20030117
	CA 2513170	A1	20040805	CA 2004-2513170	20040115
	EP 1600166	A1	20051130	EP 2004-702450	20040115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006052362	A1	20060309	US 2005-542322	20050713
PRAI	JP 2003-10125	A	20030117		
	JP 2003-93591	A	20030331		
	JP 2002-10623	A	20020118		
	WO 2004-JP234	W	20040115		

OS MARPAT 141:162403

AB It is intended to provide a novel drug useful as a skeletal muscle protecting agent which contains a compound having an effect of inhibiting squalene synthase, its salt or a prodrug thereof. The agent of the present invention is suitable for use for protecting skeletal muscle from cytotoxicity due to usage of other drug, e.g. HMG-CoA reductase inhibitor. The effect of N-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid on muscle geranylgeraniol content in rats was examined

IT 189059-71-0 189060-13-7 383652-98-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(skeletal muscle protecting agents containing squalene synthase inhibitors)

RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:885310 CAPLUS Full-text  
 DN 140:174823  
 TI Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes  
 AU Nishimoto, Tomoyuki; Tozawa, Ryuichi; Amano, Yuichiro; Wada, Takeo; Imura, Yoshimi; Sugiyama, Yasuo  
 CS Pharmaceutical Research Division, Pharmacology Research Laboratories I, Takeda Chemical Industries, Ltd., Yodogawa-ku, Osaka, 532-8686, Japan  
 SO Biochemical Pharmacology (2003), 66(11), 2133-2139  
 CODEN: BCPA6; ISSN: 0006-2952  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 AB TAK-475 is a squalene synthase inhibitor, rapidly metabolized to T-91485 in vivo. We investigated the myotoxicities of T-91485 and 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors in a human rhabdomyosarcoma cell line, RD, and in human skeletal myocytes. In differentiated RD cells, T-91485, atorvastatin (ATV) and simvastatin acid (SIM) inhibited cholesterol biosynthesis, with ic50 values of 36, 2.8 and 3.8 nM, resp. ATV and SIM decreased the intracellular ATP content, with ic25 values (concns. giving a 25% decrease in intracellular ATP content) of 0.61 and 0.44  $\mu$ M, resp. Although T-91485 potentially inhibited cholesterol synthesis in RD cells, the ic25 value exceeded 100  $\mu$ M. In human skeletal myocytes, T-91485, ATV and SIM concentration-dependently inhibited cholesterol biosynthesis, with ic50 values of 45, 8.6 and 8.4 nM, resp. ATV and SIM decreased intracellular ATP content, with ic25 values of 2.1 and 0.72  $\mu$ M, resp. Although T-91485 potentially inhibited cholesterol synthesis, the ic25 value exceeded 100  $\mu$ M. Myotoxicity induced by ATV was prevented by mevalonate or geranylgeranyl-PP, but not by squalene in skeletal cells. Furthermore, T-91485 attenuated the myotoxicity of ATV. These findings suggest that TAK-475 and T-91485 may not only be far from myotoxic, they may also decrease statin-induced myotoxicity in lipid-lowering therapy.  
 IT 189059-71-0, T 91485  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors in human myocytes)  
 RN 189059-71-0 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L5 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:767796 CAPLUS Full-text  
 DN 139:276921  
 TI Preparation of benzoxazepine derivatives as squalene synthetic enzyme inhibitors  
 IN Miki, Takashi; Kori, Masaki  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 36 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003277377	A	20031002	JP 2003-10125	20030117
	CA 2513170	A1	20040805	CA 2004-2513170	20040115
	WO 2004064865	A1	20040805	WO 2004-JP234	20040115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	EP 1600166	A1	20051130	EP 2004-702450	20040115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2004107361	A	20040408	JP 2004-9836	20040116
	JP 2004315500	A	20041111	JP 2004-9617	20040116
	US 2006052362	A1	20060309	US 2005-542322	20050713
PRAI	JP 2002-10623	A	20020118		
	JP 2003-10125	A	20030117		
	JP 2003-93591	A	20030331		
	WO 2004-JP234	W	20040115		
OS	MARPAT 139:276921				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I [wherein W = halo; R1 = alkyl; R2 = CHO or (un)substituted alkyl; m = 1-3; n = 0-2; R4 = H or -(CH2)p-R5; R5 = (un)substituted CO2H; p = 0-3; etc.] and salts and prodrugs thereof are prepared as squalene synthetic enzyme inhibitors. I are useful as a lipid decrease medicine and a high fat blood disease medicine (no data). Thus, the compound II was prepared in a multi-step synthesis. II showed IC50 of 45 nM against human squalene synthetic enzyme. Formulations containing I as an active ingredient were also described.

IT 606928-79-4P


RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-79-4 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 606928-80-7P 606928-81-8P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-80-7 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 606928-81-8 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 606928-73-8P 606928-75-0P 606928-77-2P  
606928-78-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)

RN 606928-73-8 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,6-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-75-0 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-3-[2-(3,4-dihydro-1(2H)-pyridinyl)-2-oxoethyl]-5-(2,3-dimethoxyphenyl)-1,5-dihydro-, (3R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-77-2 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethyl-3-oxopropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-78-3 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 383652-98-0P 606928-74-9P 606928-76-1P  
606928-82-9P 606928-83-0P 606929-11-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of benzoxazepine derivs. as squalene synthetic  
enzyme inhibitors)

RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 606928-74-9 CAPLUS

CN 4-Pyridineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]acetyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-76-1 CAPLUS

CN Pyridine, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-  
1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-82-9 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-(3-hydroxy-2-methoxyphenyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606928-83-0 CAPLUS


CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-(2-hydroxy-3-methoxyphenyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 606929-11-7 CAPLUS  
 CN 4-Pyridineacetic acid, 1-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 606928-85-2P 606928-96-5P 606928-97-6P  
 606928-98-7P 606929-03-7P 606929-04-8P  
 606929-09-3P 606929-10-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of benzoxazepine derivs. as squalene synthetic enzyme inhibitors)  
 RN 606928-85-2 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(5-hydroxypentyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 606928-96-5 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(tetrahydro-2-oxo-2H-pyran-4-yl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 606928-97-6 CAPLUS

CN Pentanoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-5-hydroxy-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 606928-98-7 CAPLUS

CN Pentanoic acid, 3-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-5-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 606929-03-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-1,2,3,5-tetrahydro-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-04-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-[2-methoxy-3-(phenylmethoxy)phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-09-3 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-1,2,3,5-tetrahydro-5-[3-methoxy-2-(phenylmethoxy)phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 606929-10-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-5-[3-methoxy-2-(phenylmethoxy)phenyl]-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:584090 CAPLUS Full-text

DN 139:240092

TI Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro

AU Nishimoto, Tomoyuki; Amano, Yuichiro; Tozawa, Ryuichi; Ishikawa, Eiichiro; Imura, Yoshimi; Yukimasa, Hidefumi; Sugiyama, Yasuo

CS Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd, Osaka, 532-8686, Japan

SO British Journal of Pharmacology (2003), 139(5), 911-918  
CODEN: BJPCBM; ISSN: 0007-1188

PB Nature Publishing Group

DT Journal

LA English

AB Squalene synthase is the enzyme that converts farnesyl pyrophosphate to squalene in the cholesterol biosynthesis pathway. We examined the lipid-lowering properties of 1-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid (TAK-475), a novel squalene synthase inhibitor. TAK-475 inhibited hepatic cholesterol biosynthesis in rats (ED<sub>50</sub>, 2.9 mg kg<sup>-1</sup>) and showed lipid-lowering effects in beagle dogs, marmosets, cynomolgus monkeys and Wistar fatty rats. In marmosets, TAK-475 (30, 100 mg kg<sup>-1</sup>, p.o., for 4 days) lowered both plasma non-high-d. lipoprotein (HDL) cholesterol and triglyceride, but did not affect plasma HDL cholesterol. Atorvastatin (10, 30 mg kg<sup>-1</sup>, p.o., for 4 days) lowered the levels of all these lipids. A correlation between decrease in triglyceride and increase in HDL cholesterol was observed, and TAK-475 increased HDL cholesterol with a smaller decrease in triglyceride than did atorvastatin. TAK-475 (60 mg kg<sup>-1</sup>, p.o., for 15 days) suppressed the rate of triglyceride secretion from the liver in hypertriglyceridemic Wistar fatty rats, which show an enhanced triglyceride secretion rate from the liver compared with their lean littermates. In HepG2 cells, TAK-475 and its pharmacol. active metabolite, T-91485, increased the binding of <sup>125</sup>I-low-d. lipoprotein (LDL) to LDL receptors. These results suggest that TAK-475 has clear hypolipidemic effects in animals via inhibition of hepatic triglyceride secretion and upregulation of LDL receptors, and that TAK-475 might increase HDL cholesterol by decreasing triglyceride. Thus, TAK-475 is expected to be useful for the treatment of dyslipidemia.


IT 189060-13-7, TAK 475

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lipid-lowering properties of TAK-475)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 189059-71-0

RL: PAC (Pharmacological activity); BIOL (Biological study)  
(lipid-lowering properties of TAK-475)

RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:249806 CAPLUS Full-text  
 DN 139:173582  
 TI Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in  
 animal models of familial hypercholesterolemia  
 AU Amano, Yuichiro; Nishimoto, Tomoyuki; Tozawa, Ryu-Ichi; Ishikawa,  
 Eiichiro; Imura, Yoshimi; Sugiyama, Yasuo  
 CS Pharmaceutical Research Division, Pharmacology Research Laboratories II,  
 Takeda Chemical Industries, Ltd., 2-17-85, Juso-Honmachi, Osaka, Yodogawa,  
 532-8686, Japan  
 SO European Journal of Pharmacology (2003), 466(1-2), 155-161  
 CODEN: EJPHAZ; ISSN: 0014-2999  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 AB The lipid-lowering effects of 1-{2-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-  
 7-chloro-1,2,3,5-tetrahydro-2-oxo-5-(2,3-dimethoxyphenyl)-4,1-benzoxazepine-  
 3-yl] acetyl} piperidin-4-acetic acid (TAK-475), a novel squalene synthase  
 inhibitor, were examined in two models of familial hypercholesterolemia, low-  
 d. lipoprotein (LDL) receptor knockout mice and Watanabe heritable  
 hyperlipidemic (WHHL) rabbits. Two weeks of treatment with TAK-475 in a diet  
 admixt. (0.02% and 0.07%; approx. 30 and 110 mg/kg/day, resp.) significantly  
 lowered plasma non-high-d. lipoprotein (HDL) cholesterol levels by 19% and  
 41%, resp., in homozygous LDL receptor knockout mice. The 3-hydroxy-3-  
 methylglutaryl CoA (HMG-CoA) reductase inhibitors, simvastatin and  
 atorvastatin (in 0.02% and 0.07% admixts.), also reduced plasma levels of non-  
 HDL cholesterol. In homozygous WHHL rabbits, 4 wk of treatment with TAK-475  
 (0.27%; approx. 100 mg/kg/day) lowered plasma total cholesterol, triglyceride  
 and phospholipid levels by 17%, 52% and 26%, resp. In Triton WR-1339-treated  
 rabbits, TAK-475 inhibited to the same extent the rate of secretion from the  
 liver of the cholesterol, triglyceride and phospholipid components of very-  
 low-d. lipoprotein (VLDL). These results suggest that the lipid-lowering  
 effects of TAK-475 in WHHL rabbits are based partially on the inhibition of  
 secretion of VLDL from the liver. TAK-475 had no effect on plasma aspartate  
 aminotransferase and alanine aminotransferase activities. Thus, the squalene  
 synthase inhibitor TAK-475 revealed lipid-lowering effects in both LDL  
 receptor knockout mice and WHHL rabbits.  
 IT 189060-13-7, TAK 475  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in  
 animal models of familial hypercholesterolemia)  
 RN 189060-13-7 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-  
 dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-  
 4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:22711 CAPLUS Full-text

DN 138:83384

TI Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase

IN Sugiyama, Yasuo; Nishimoto, Tomoyuki; Kiyota, Yoshihiro

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2003002147	A1	20030109	WO 2002-JP6495	20020627
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2451163	A1	20030109	CA 2002-2451163	20020627
	AU 2002313277	A1	20030303	AU 2002-313277	20020627
	JP 2003081873	A	20030319	JP 2002-188133	20020627
	EP 1407782	A1	20040414	EP 2002-738822	20020627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004204500	A1	20041014	US 2003-480707	20031211
	US 2006241096	A1	20061026	US 2006-473560	20060623
PRAI	JP 2001-197419	A	20010628		
	WO 2002-JP6495	W	20020627		
	US 2003-480707	A3	20031211		

OS MARPAT 138:83384

AB Preventives/remedies for organ functional disorders, preventives/remedies for organ dysfunction and preventives/remedies for obesity and sequels thereof which contain a compound having an effect of increasing ubiquinone, its salt or prodrugs of the same; and ubiquinone increasing agents containing a compound having a squalene synthase inhibitory effect, its salt or prodrugs of the same.

IT 383652-98-0P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)

RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



IT 189058-78-4, N-[[[(3R,5S)-1-(2,2-Dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-Benzoxazepin-3-yl]acetyl]piperidineacetic acid 189059-19-6 189059-57-2  
 189059-71-0, N-[[[(3R,5S)-1-(3-Hydroxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-Benzoxazepin-3-yl]acetyl]piperidineacetic acid 189059-84-5 189059-85-6  
 189060-04-6, Ethyl N-[[[(3R,5S)-1-(3-Acetoxy-2-acetoxy-2-methylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-Benzoxazepin-3-yl]acetyl]piperidineacetate 189060-07-9  
 189060-10-4, Ethyl N-[[[(3R,5S)-1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidineacetate 189060-21-7 189060-33-1  
 189060-37-5 189060-41-1 189060-45-5  
 189060-48-8 383652-05-9 383652-11-7  
 383652-16-2 383652-22-0 383652-28-6  
 383652-33-3 383652-38-8 383652-44-6,  
 Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- 383652-50-4 383652-56-0  
 383652-61-7 383652-66-2 383652-71-9  
 383652-76-4 383652-81-1 383652-87-7  
 383652-92-4 383654-65-7, Benzenepropanoic acid,  
 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-  
 383657-83-8 383662-50-8  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (Preventives/remedies for organ functional disorders with increasing  
 ubiquinone and inhibiting squalene synthase)  
 RN 189058-78-4 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[[[7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-,  
 (3R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-57-2 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-(3-hydroxy-2,2-dimethylpropyl)-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-84-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-85-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-04-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 189060-07-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-10-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[ (3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-21-7 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidiny)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-, (3R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-45-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-48-8 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-05-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-(propylsulfonyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-11-7 CAPLUS

CN D-Alanine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-16-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-22-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383652-28-6 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383652-33-3 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-38-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-44-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-50-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-56-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-61-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-66-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-71-9 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-76-4 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-81-1 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-87-7 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-92-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-65-7 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-83-8 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-50-8 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 383654-76-0P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP


(Preparation); RACT (Reactant or reagent)

(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)

RN 383654-76-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 189060-13-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)

RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:664428 CAPLUS Full-text  
DN 137:337866  
TI Synthesis of Novel 4,1-Benzoxazepine Derivatives as Squalene Synthase  
Inhibitors and Their Inhibition of Cholesterol Synthesis  
AU Miki, Takashi; Kori, Masakuni; Mabuchi, Hiroshi; Tozawa, Ryu-ichi;  
Nishimoto, Tomoyuki; Sugiyama, Yasuo; Teshima, Koichiro; Yukimasa,  
Hidefumi  
CS Pharmaceutical Research Division, Takeda Chemical Industries Ltd.,  
Yodogawa-ku, Osaka, 532-8686, Japan  
SO Journal of Medicinal Chemistry (2002), 45(20), 4571-4580  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 137:337866  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Modification of the carboxyl group at the 3-position and introduction of  
protective groups to the hydroxy group of the 4,1-benzoxazepine derivative I  
(R = OH) [metabolite of I (R = H) Na salt] were carried out, and the  
inhibitory activity for squalene synthase and cholesterol synthesis in the  
liver was investigated. Among these compds., the glycine derivative II (n =  
1) and  $\beta$ -alanine derivative II (n = 2) exhibited the most potent inhibition of  
squalene synthase prepared from HepG2 cells (IC<sub>50</sub> = 15 nM). On the other hand,  
the piperidine-4-acetic acid derivative III (R<sub>1</sub> = Ac), which was prepared by  
acetylation of III (R<sub>1</sub> = H), was the most effective inhibitor of cholesterol  
synthesis in rat liver (ED<sub>50</sub> = 2.9 mg/kg, po). After oral administration, III  
(R<sub>1</sub> = Ac) was absorbed and rapidly hydrolyzed to III (R<sub>1</sub> = H). Compound III  
(R<sub>1</sub> = H) was detected mainly in the liver, but the plasma level of III (R<sub>1</sub> =  
H) was found to be low. Compds. III (R<sub>1</sub> = H, Ac) were found to be competitive  
inhibitors with respect to farnesyl pyrophosphate. Further evaluation of III  
(R<sub>1</sub> = Ac) as a cholesterol-lowering and antiatherosclerotic agent is underway.

IT 189059-71-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant  
or reagent)


(preparation of 4,1-benzoxazepines as squalene synthase inhibitors and  
their inhibition of cholesterol synthesis)

RN 189059-71-0 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 189059-72-1P 189060-13-7P 383653-71-2P  
 383654-03-3P 383654-14-6P 383658-74-0P  
 383658-84-2P 473987-15-4P 473987-16-5P  
 473987-17-6P 473987-18-7P 473987-19-8P  
 473987-25-6P 473987-26-7P 473987-27-8P  
 473987-28-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)

(preparation of 4,1-benzoxazepines as squalene synthase inhibitors and  
 their inhibition of cholesterol synthesis)

RN 189059-72-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
 1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
 3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-  
 dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-  
 4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 383653-71-2 CAPLUS

CN D-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383654-03-3 CAPLUS

CN L-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-14-6 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-74-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383658-84-2 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-15-4 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-16-5 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-17-6 CAPLUS

CN  $\beta$ -Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-18-7 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-19-8 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-25-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-26-7 CAPLUS


CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxobutoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 473987-27-8 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(2-methyl-1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 473987-28-9 CAPLUS  
 CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[(2,2-dimethyl-1-oxopropoxy)methoxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 189059-65-2P 189059-66-3P 383661-79-8P  
 383662-10-0P 383662-15-5P 383669-08-7P  
 383669-14-5P 473987-08-5P 473987-09-6P  
 473987-10-9P 473987-13-2P 473987-14-3P  
 473987-20-1P 473987-21-2P 473987-22-3P  
 473987-23-4P 473987-24-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4,1-benzoxazepines as squalene synthase inhibitors and


their

inhibition of cholesterol synthesis)

RN 189059-65-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-66-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 383661-79-8 CAPLUS

CN D-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 383662-10-0 CAPLUS

CN L-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-15-5 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-08-7 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-14-5 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-08-5 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-09-6 CAPLUS

CN Glycine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-N-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-10-9 CAPLUS

CN  $\beta$ -Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-13-2 CAPLUS

CN 4-Piperidinepropanoic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-14-3 CAPLUS

CN 4-Piperidinebutanoic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-20-1 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN. 473987-21-2 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-22-3 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(1-oxobutoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-23-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[2,2-dimethyl-3-(2-methyl-1-oxopropoxy)propyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 473987-24-5 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-[3-[(2,2-dimethyl-1-oxopropoxy)methoxy]-2,2-dimethylpropyl]-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:368342 CAPLUS Full-text  
 DN 136:359669  
 TI High-density lipoprotein-cholesterol level elevating agent  
 IN Nishimoto, Tomoyuki; Tozawa, Ryuichi; Kori, Masakuni; Amano, Yuichiro  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 111 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038180	A1	20020516	WO 2001-JP9802	20011109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2428669	A1	20020516	CA 2001-2428669	20011109
	AU 2002012741	A5	20020521	AU 2002-12741	20011109
	JP 2002205956	A	20020723	JP 2001-344074	20011109
	EP 1332763	A1	20030806	EP 2001-981043	20011109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004063750	A1	20040401	US 2003-416239	20030506
PRAI	JP 2000-342607	A	20001109		
	WO 2001-JP9802	W	20011109		
OS	MARPAT 136:359669				
AB	Disclosed is a novel high-d. lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory effect. The HDL-cholesterol-elevating effect of N-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]acetyl]piperidine-4-acetic acid (I) in common marmoset was examined Also, a tablet containing I 50, D-mannitol 50, corn starch 33.9, croscarmellose sodium 40, hydroxypropyl cellulose 5.5, and magnesium stearate 0.6 mg was prepared				
IT	189060-05-7				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (high-d. lipoprotein-cholesterol level elevating agents containing squalene synthase inhibitors)				
RN	189060-05-7 CAPLUS				
CN	4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




IT 189058-97-7 189059-19-6 189059-57-2  
 189059-70-9 189059-84-5 189059-85-6  
 189060-04-6 189060-07-9 189060-10-4  
 189060-13-7 189060-21-7 189060-33-1  
 189060-37-5 189060-45-5 189060-48-8  
 383652-05-9 383652-11-7 383652-22-0  
 383652-28-6 383652-33-3 383652-38-8  
 383652-44-6 383652-50-4 383652-66-2  
 383652-71-9 383652-76-4 383652-81-1  
 383652-92-4 383652-98-0 383654-76-0  
 383657-83-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (high-d. lipoprotein-cholesterol level elevating agents containing squalene  
 synthase inhibitors)

RN 189058-97-7 CAPLUS

CN  $\beta$ -Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189059-19-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 189059-57-2 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-(3-hydroxy-2,2-dimethylpropyl)-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 189059-70-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-84-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189059-85-6 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-04-6 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-07-9 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-10-4 CAPLUS

CN 4-Piperidineacetic acid, 1-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-13-7 CAPLUS

CN 4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-21-7 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-33-1 CAPLUS

CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-37-5 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-2-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189060-45-5 CAPLUS


CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189060-48-8 CAPLUS  
 CN 4,1-Benzoxazepin-2(3H)-one, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,5-dihydro-3-(1H-tetrazol-5-ylmethyl)-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 383652-05-9 CAPLUS  
 CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-(propylsulfonyl)-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 383652-11-7 CAPLUS  
 CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-22-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-28-6 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-33-3 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-38-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 383652-44-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 383652-50-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-66-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-71-9 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-76-4 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-81-1 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-92-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-98-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383654-76-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383657-83-8 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]- (9CI) (CA INDEX NAME)



Absolute stereochemistry. Rotation (-).



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:935587 CAPLUS Full-text  
 DN 136:69829  
 TI Preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents  
 IN Kori, Masakuni; Miki, Takashi; Nishimoto, Tomoyuki; Tozawa, Ryuichi  
 PA Takeda Chemical Industries, Ltd, Japan  
 SO PCT Int. Appl., 643 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2001098282	A1	20011227	WO 2001-JP5347	20010622
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2413429	A1	20011227	CA 2001-2413429	20010622
	AU 200174588	A	20020102	AU 2001-74588	20010622
	JP 2002080468	A	20020319	JP 2001-189417	20010622
	JP 2003064063	A	20030305	JP 2002-233086	20010622
	EP 1292585	A1	20030319	EP 2001-941174	20010622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011835	A	20030429	BR 2001-11835	20010622
	HU 200301301	A2	20030828	HU 2003-1301	20010622
	US 2003078251	A1	20030424	US 2002-203524	20020809
	ZA 2002009055	A	20031107	ZA 2002-9055	20021107
	MX 2002PA12481	A	20030606	MX 2002-PA12481	20021216
	NO 2002006164	A	20021220	NO 2002-6164	20021220
PRAI	JP 2000-190253	A	20000623		
	JP 2001-189417	A3	20010622		
	WO 2001-JP5347	W	20010622		
OS	MARPAT 136:69829				
GI					



AB Alkoxyphenyloxobenzoxazepineacetamides [I; R = (un)substituted 1-carboxyethyl, (un)substituted carboxyalkyl, sulfonylalkyl, (carboxycycloalkyl)alkyl, etc.; R1 = alkyl (un)substituted with alkanoyloxy or OH groups (if R = (un)substituted 1-carboxyethyl, alkyl, 4-carboxycyclohexylmethyl, or 4-carboxyphenylmethyl, then R1 must be substituted with a OH or alkanoyloxy group); R2 = lower alkyl; W = halogen] are prepared as squalene synthase

inhibitors for the treatment of hyperlipidemia and the decrease of serum triglycerides and lipids. (3R, 4S)-I [R = Me(CH<sub>2</sub>)<sub>2</sub>SO<sub>2</sub>; R<sub>1</sub> = HOCH<sub>2</sub>C(Me)<sub>2</sub>CH<sub>2</sub>; R<sub>2</sub> = Me; W = Cl] (II) was prepared in 3 steps from hydroxyacid (III) by acetylation of the hydroxyl group with acetic anhydride, treatment of the acid with thionyl chloride in THF to generate the acid chloride in situ, and addition of the mixture to a solution of PrSO<sub>2</sub>NH<sub>2</sub> in THF to provide the acetylated methoxyphenyloxobenzoxazepineacetamide I [R = PrSO<sub>2</sub>; R<sub>1</sub> = AcOCH<sub>2</sub>C(Me)<sub>2</sub>CH<sub>2</sub>; R<sub>2</sub> = Me; W = Cl]; hydrolysis of the acetoxy group with aqueous sodium hydroxide and ethanol provides II. Data for the inhibition of squalene synthase by I are given. Pharmaceutical compns. containing I [R = 3-(HO<sub>2</sub>CCH<sub>2</sub>CH<sub>2</sub>)C<sub>6</sub>H<sub>4</sub>; R<sub>1</sub> = HOCH<sub>2</sub>CMe<sub>2</sub>CH<sub>2</sub>; R<sub>2</sub> = Me; W = Cl] are specified.

IT 383661-74-3P 383661-79-8P 383661-85-6P  
 383661-90-3P 383661-95-8P 383662-00-8P  
 383662-05-3P 383662-10-0P 383662-15-5P  
 383662-20-2P 383662-25-7P 383662-50-8P  
 383662-71-3P 383662-81-5P 383662-97-3P  
 383663-24-9P 383663-35-2P 383663-76-1P  
 383664-02-6P 383664-07-1P 383664-12-8P  
 383664-18-4P 383664-35-5P 383664-54-8P  
 383664-99-1P 383665-26-7P 383665-43-8P  
 383665-48-3P 383665-62-1P 383665-76-7P  
 383666-12-4P 383666-22-6P 383666-37-3P  
 383666-63-5P 383666-68-0P 383666-96-4P  
 383667-27-4P 383667-32-1P 383667-37-6P  
 383667-42-3P 383667-47-8P 383667-52-5P  
 383667-58-1P 383667-63-8P 383667-69-4P  
 383667-74-1P 383667-79-6P 383667-84-3P  
 383667-89-8P 383667-94-5P 383668-00-6P  
 383668-05-1P 383668-10-8P 383668-26-6P  
 383668-39-1P 383668-63-1P 383668-88-0P  
 383669-02-1P 383669-08-7P 383669-14-5P  
 383669-23-6P 383669-33-8P 383669-42-9P  
 383669-51-0P 383669-66-7P 383669-82-7P  
 383670-03-9P 383670-28-8P 383670-38-0P  
 383670-49-3P 383670-59-5P 383670-64-2P  
 383670-69-7P 383670-85-7P 383671-02-1P  
 383671-23-6P 383671-45-2P 383671-60-1P  
 383671-79-2P 383672-12-6P 383672-25-1P  
 383672-30-8P 383672-35-3P 383672-40-0P  
 383672-50-2P 383672-67-1P 383672-82-0P  
 383672-88-6P 383672-95-5P 383673-01-6P  
 383673-16-3P 383673-32-3P 383673-59-4P  
 383673-75-4P 383674-10-0P 383674-38-2P  
 383674-55-3P 383674-72-4P 383674-89-3P  
 383674-95-1P 383675-11-4P 383675-45-4P  
 383675-68-1P 383675-90-9P 383676-16-2P  
 383676-57-1P 383676-81-1P 383677-02-9P  
 383677-82-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediates; preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)

RN 383661-74-3 CAPLUS

CN L-Leucine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-79-8 CAPLUS

CN D-Leucine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-85-6 CAPLUS

CN D-Leucine, N-[[ (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-90-3 CAPLUS

CN L-Methionine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383661-95-8 CAPLUS

CN D-Methionine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 383662-00-8 CAPLUS

CN D-Methionine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 383662-05-3 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-10-0 CAPLUS

CN L-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-15-5 CAPLUS

CN D-Alanine, N-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-20-2 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-25-7 CAPLUS

CN Cyclohexanepropanoic acid,  $\alpha$ -[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383662-50-8 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-71-3 CAPLUS

CN 2,4-Furandicarboxylic acid, 5-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-81-5 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383662-97-3 CAPLUS

CN Benzeneacetic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383663-24-9 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383663-35-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383663-76-1 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-02-6 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-07-1 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-12-8 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-18-4 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-35-5 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-ethoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383664-54-8 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(1-methylethoxy)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383664-99-1 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383665-26-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383665-43-8 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383665-48-3 CAPLUS

CN Benzenecetic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383665-62-1 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383665-76-7 CAPLUS

CN Benzenecetic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-12-4 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-22-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383666-37-3 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,5-dimethoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-63-5 CAPLUS

CN Benzenebutanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-68-0 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383666-96-4 CAPLUS

CN Benzenepropanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME).


Absolute stereochemistry. Rotation (-).



RN 383667-27-4 CAPLUS

CN Benzoic acid, 4-[[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-32-1 CAPLUS

CN Propanoic acid, 2-[4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-37-6 CAPLUS

CN Acetic acid, [4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-42-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-47-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-52-5 CAPLUS

CN Benzoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-58-1 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-63-8 CAPLUS

CN Benzoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383667-69-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383667-74-1 CAPLUS

CN 4-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-79-6 CAPLUS

CN 2-Furancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-84-3 CAPLUS

CN Benzeneacetic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-89-8 CAPLUS

CN Benzoic acid, 4-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383667-94-5 CAPLUS

CN Benzoic acid, 3-[3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-00-6 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-05-1 CAPLUS

CN Benzoic acid, 4-[2-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-10-8 CAPLUS

CN Benzoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-26-6 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383668-39-1 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-63-1 CAPLUS

CN Benzenebutanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383668-88-0 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-02-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5,6,7,8-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-08-7 CAPLUS

CN Butanoic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-14-5 CAPLUS

CN Pentanoic acid, 5-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-23-6 CAPLUS

CN Hexanoic acid, 6-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-33-8 CAPLUS

CN 3-Furancarboxylic acid, 2-[2-[[[(3S,5R)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 383669-42-9 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3S,5R)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 383669-51-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3S,5R)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).






RN 383669-66-7 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-chloro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383669-82-7 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-(3-phenylpropoxy)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383670-03-9 CAPLUS


CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(3-phenylpropoxy)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 383670-28-8 CAPLUS

CN 1-Naphthalenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5,6,7,8-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-38-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 6-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383670-49-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-59-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-64-2 CAPLUS

CN Benzoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-69-7 CAPLUS

CN Benzoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383670-85-7 CAPLUS

CN Acetic acid, [4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]phenoxy]difluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383671-02-1 CAPLUS

CN Acetic acid, [3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]phenoxy]difluoro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383671-23-6 CAPLUS

CN Benzenepropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383671-45-2 CAPLUS

CN Benzenepentanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383671-60-1 CAPLUS

CN Acetic acid, [4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-fluorophenoxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383671-79-2 CAPLUS

CN Benzeneacetic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- $\alpha,\alpha$ -dimethyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-12-6 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- $\gamma,\gamma$ -dimethyl-, ethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-25-1 CAPLUS

CN Benzenepentanoic acid, 4-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 383672-30-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383672-35-3 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-40-0 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-50-2 CAPLUS

CN 5-Thiazoleacetic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-67-1 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-82-0 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-88-6 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383672-95-5 CAPLUS

CN 5-Thiazolepropanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-phenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-01-6 CAPLUS

CN 5-Thiazolebutanoic acid, 2-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-16-3 CAPLUS

CN Acetic acid, [[5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-1H-benzimidazol-2-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-32-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-methoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-59-4 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-ethoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383673-75-4 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-propoxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-10-0 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-(1-methylethoxy)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-38-2 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-55-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-propoxy-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-72-4 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-(2-ethoxy-2-oxoethoxy)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-89-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-(1-methylethoxy)-, ethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383674-95-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).






RN 383675-11-4 CAPLUS

CN Benzo[b]thiophene-2-carboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383675-45-4 CAPLUS

CN 2-Benzofuranpropanoic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383675-68-1 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383675-90-9 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383676-16-2 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-ethyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383676-57-1 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-7-propyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383676-81-1 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4,6,7-trimethyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383677-02-9 CAPLUS

CN 2-Benzofurancarboxylic acid, 7-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-5-chloro-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383767-82-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 383652-33-3P 383652-44-6P 383652-56-0P  
 383652-66-2P 383652-92-4P 383652-98-0P  
 383653-04-1P 383653-14-3P 383653-20-1P  
 383653-31-4P 383653-40-5P 383653-71-2P  
 383654-03-3P 383654-14-6P 383654-54-4P  
 383654-65-7P 383654-88-4P 383654-99-7P  
 383655-09-2P 383655-19-4P 383655-31-0P  
 383655-41-2P 383655-52-5P 383655-73-0P  
 383655-93-4P 383656-19-7P 383656-30-2P  
 383656-42-6P 383656-68-6P 383656-78-8P  
 383656-90-4P 383657-01-0P 383657-12-3P  
 383657-22-5P 383657-38-3P 383657-50-9P  
 383657-61-2P 383657-72-5P 383657-83-8P  
 383657-94-1P 383658-05-7P 383658-15-9P  
 383658-25-1P 383658-36-4P 383658-46-6P  
 383658-84-2P 383658-95-5P 383659-31-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(title compds.; preparation of dialkoxyphenyloxobenzoxazepineacetamide

squalene synthase inhibitors as antihyperlipidemic and  
antihypercholesteremic agents)

RN 383652-33-3 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]acetyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 383652-44-6 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]acetyl]amino]-4-methyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-56-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-  
1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-  
3-yl]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383652-66-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 383652-92-4 CAPLUS

CN Benzenepropanoic acid, 3-[[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]amino]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

